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Abstract

In the heart, electrical signaling is responsible for its rhythmicity and is necessary
to initiate muscle contraction. The net electrical activity in a cardiac myocyte during a
contraction cycle is observed as the action potential (AP), which describes a change in
membrane potential as a function of time. In ventricular cardiac myocytes, voltage-gated
sodium channels (Nav) and voltage-gated potassium channels (Kv) play antagonistic roles
in shaping the AP with the former initiating membrane depolarization and the latter
repolarizing it. Functional changes in the primary cardiac Nav isoform, Nav 1.5, or any
one of the many Kv isoforms expressed in the ventricle, as evidenced by those
characterized in various congenital and/or acquired etiologies, can lead to severe cardiac
pathologies. Nav and Kv are large transmembrane proteins that can be extensively posttranslationally modified through processes that include glycosylation. The sequential
glycosylation process typically ends with negatively charged sialic acid residues added
through trans-Golgi sialyltransferase activity. Sialyltransferases belong to a much larger
group of glycogene products that number in the hundreds and are responsible for creating
a complex and variable glycan profile (glycome) unique to different cell types and
tissues. Sialic acids impact Nav and Kv function likely by contributing to the extracellular
surface potential and thereby causing channels to gate following smaller depolarizations.
Additionally, developmentally regulated sialylation contributes to cardiac myocyte
excitability in the neonatal mouse atria. However, little is understood concerning how
x

the glycosylation machinery (glycogene products) influences cell and tissue electrical
signaling.
The sialytransferase β-galactoside α-2,3-sialyltransferase 4 (ST3Gal4) adds sialic
acids to galactose residues of N- and O-linked glycans through α-2,3-linkgages.
ST3Gal4 is uniformly expressed throughout the chambers and developmental stages of
the heart and therefore is likely a useful target to question whether and how glycosylation
impacts these events. Additionally, diseases of glycosylation often cause symptoms that
are consistent with changes in excitability that include arrhythmias and seizures.
Congenital disorders of glycosylation lead to variably reduced glycoprotein and
glycolipid glycosylation.

However, because sialic acids are typically the terminal

residues added to glycan structures, disease-related reduced glycosylation often leads to
fewer sialic acids being attached.

In addition, Chagas disease, which results in

pathological changes in cardiac electrical function, may reduce sialic acids directly.
Because of this, the ST3Gal4-/- strain was also used to investigate the role of
glycosylation in the pathological cardiac electrical remodeling often associated with these
diseases.

The

methodologies

included

cellular,

tissue

and

whole-animal

electrophysiology as well as biochemical assays. The data indicate that deletion of
ST3Gal4 significantly affects Nav sialylation and gating with no change in maximum
current density or protein expression. ST3Gal4 deletion also depolarizes the activation
gating of both voltage-dependent kinetic components of repolarization found in the
mouse ventricle: Ito and IKslow; however unlike the effect on INa, ST3Gal4 gene deletion
causes a reduction in the peak IK density. Protein expression of the putative Kv isoforms
responsible for Ito and IKslow was variably affected by ST3Gal4 gene deletion with Kv1.5
xi

and Kv4.2 demonstrating no differences in protein densities. Contrastingly, a small but
significant reduction in Kv2.1 protein from ST3Gal4-/- ventricular tissue was observed. In
addition to effects on Nav and Kv activity, ST3Gal4 expression is necessary for normal
cellular electrical signaling as demonstrated by a reduction in cellular refractory period
and alterations in AP waveforms that include a slowing of cellular conduction and an
extension of AP duration in ventricular myocytes from ST3Gal4-/- mice. Concurrent with
aberrant excitability at the cellular level, the ST3Gal4-/- left ventricular epicardium
demonstrated a reduced refractory period and was more susceptible to arrhythmias as
observed through optical mapping studies. Additionally, ECGs of ambulatory ST3Gal4-/mice demonstrated that deletion of the gene causes modest aberrant conduction under
basal conditions and, in preliminary studies, appears to increase susceptibility to
arrhythmias following a cardiac challenge, in the form of a low dosage of the βadrenergic agonist isoproterenol, suggesting a reduction in repolarization reserve in
ST3Gal4 hearts. Based on the data reported here, it is apparent that relatively minor
perturbations in the cardiac glycome cause significant changes in cardiac electrical
signaling. These data highlight the role of glycosylation in normal physiology and
underscore it as an important mediator in diseases where it may be altered.
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Chapter 1
Introduction

1.1. A historical perspective on electrophysiology and the role of voltage-gated ion
channels in excitability
Electrical signaling is a vital biological function that developed concurrently with
the evolution of increasingly sophisticated organisms and presumably facilitated that
evolution[1-4].

Electrical signaling not only provides a rapid means of intra- and

extracellular communication vital to the integration of different organs and physiological
systems but also provides a driving force and rhythmicity for many cellular functions.
Cardiac and skeletal muscle and neuronal activities are most often associated with
electrical signaling but other processes such as secretion and immune responses also
depend on the passive and active movement of ions across cellular membranes. The
modern age of electrophysiology began in the 1940s and 50s when A.L. Hodgkin, A.F.
Huxley, B. Katz, and others performed their famous experiments[5-15]. Utilizing the
axons of squid, two phenomena quintessential to the principles of electrical signaling
were described: cells are selectively permeable to ionic species and ionic flux is mediated
through voltage changes.

Through electrophysiological experiments, Hodgkin and

Huxley as well as other groups that followed, were able to describe many of the
biophysical properties of the unknown ionic transporters.

What the groups were

observing primarily was the action of a family of proteins classified as voltage-gated ion
channels (VGIC). The ability of a VGIC to sense a change in voltage and gate open to
1

create a permeation pathway for specific ions, was first described by Hodgkin and
Huxley during experiments observing Na+ currents where they predicted that the increase
in Na+ conductance depended on the movement of charged particles in response to a
change in voltage[10]. Later, this was observed directly by several groups as a relatively
small electrical current that preceded the ionic conductance through the channel and was
termed, “gating charge”[16-19]. It was discovered that the nature of this gating current
involved the movement of positively charged arginine and lysine residues in a specific
region of the channels, which is common among VGIC types[20, 21]. There are four
families of VGICs that are classified by the ion they are most specific for in a
physiological setting and include voltage-gated Ca2+ (Cav), voltage-gated Na+ (Nav),
voltage-gated K+ (Kv) and voltage-gated Cl- (ClC) channels. Typically, Nav and Kv play
oppositional roles in electrical excitability with the former “activating” or depolarizing
the cell and the latter “deactivating” or repolarizing the cell. Nav and Kv are structurally
homologous sharing a four-fold symmetry that consists of either domains, in the case of
Nav, or subunits, in the case of Kv. The difference originates from the organization of the
protein: Nav are one gene product while Kv are formed from multiple gene products
assembling in a homo- or heterotetrameric manner[22, 23].

Each subunit/domain

consists of 6 transmembrane segments and it is within these segments where the arginine
and lysine residues, which generate gating current, reside (Fig. 1.1). Specifically, the
fourth segment (S4) contains arginines and lysines every 3 to 4 residues with arginine
being the predominate amino acid found[20].

2

Figure 1.1: Structures of voltage-gated Na+ and K+ channels. A, Structure of a typical
Nav. B, Structure of a typical Kv. For both note the four-fold symmetry which differs in
that Nav are one polypeptide and Kv are four individual subunits. Figure modified from
Boron and Boulpaep Medical Physiology[24] reprinted with permission.

There are 3 prevailing theories that describe voltage-sensing: the paddle, the helical
screw and the transporter model[20]; however, the overarching theme of the 3 models is
that the S4 region(s) interacts electrostatically with the local electric field across the cell
membrane causing segments 1 through 4 to change conformation. This movement, in
turn, affects the conformation of segments 5 and 6 (the pore), which leads to voltage
dependent activity of the channel. The resting membrane potential is the source of
potential energy for VGIC activity and is created by the actions of various ionic
transporters and exchangers that create a charge gradient across the membranes of
3

excitable cells.

It is through changes in the membrane potential and electrostatic

interactions that VGICs move in and out 3 distinct conformations (gating): open, inactive
and closed. The rates and voltages at which these events occur differ considerably
between VGIC types. There are 9 mammalian Nav isoforms that all possess unique
biophysical properties and expression patterns[25].

The differential expression and

activity of these isoforms have important physiological roles. For example, Nav1.9 is
expressed in nociceptive neurons[26].

They activate at relatively hyperpolarized

potentials and inactivate slowly allowing for persistent Na+ current. It is thought that
Nav1.9 contributes little to depolarization but rather to setting the threshold for activation
and the resting membrane potential[27].

These features play a vital role in

nociception[26]. Contrastingly, Nav1.4 is primarily expressed in skeletal muscle where
cell depolarization must occur quickly and be flexible to repeated stimulation.
Concurrent with this, Nav1.4 activates rapidly, conducts a relatively large amount of Na+
and channel availability is depolarized[25, 28]. The channel also inactivates and recovers
from inactivation rapidly compared to other Nav isoforms. Kv channels are represented by
approximately 60 different isoforms that demonstrate even more variability in function
and expression than Nav[23]. Diverse tissue and cell types have developed an array of
VGIC types to meet physiological demand.

1.2. The role of electrical signaling the heart
The ability of the heart to pump blood throughout the body is dependent upon the
synchronous contraction of individual cardiomyocytes. In order to drive the machinery
of contraction, the cytosolic Ca2+ concentration must increase. Ca2+ influx into the
4

cytosol occurs via 2 pathways: a voltage sensitive extracellular pathway and a calcium
dependent intracellular pathway. The driving force for the required increase in cytosolic
Ca2+ is derived from ionic flux across the cell membrane, which contributes to excitationcontraction (E-C) coupling.

Upon activation of a cardiomyocyte, the membrane

depolarizes beginning a dynamic process that ultimately results in the influx of
extracellular Ca2+ and the Ca2+-dependent release from intracellular stores.

Upon

completion of contraction, the membrane is restored to the resting potential. In addition
to initiating contraction by increasing intracellular Ca2+, myocyte electrical signaling is
also necessary to maintain cardiac conduction and rhythmicity. A cardiac myocyte action
potential (AP)[29] varies among areas of the heart[29, 30] and among species[31] but
generally consists of 5 phases (Fig. 1.2). In atrial and ventricular myocytes inward
sodium current (INa), through Nav, causes the rapid and unstoppable depolarization of the
membrane or phase 0. While a number of Nav isoforms at the transcript or protein level
were observed[32, 33], Nav1.5 is the predominate isoform[34, 35]. The structure and
distribution of Nav1.5 is generally conserved across different species and there is
evidence that there are regional differences in the expression patterns of the channel
throughout the heart[36, 37].

Nav1.5 inactivates rapidly, on the order of a few

milliseconds (ms), which contributes to phase 1 of the AP. Interestingly the position
along the voltage axis of the voltage-dependent inactivation curve of Nav1.5 occurs in
such a place that renders few channels available at a normal myocyte resting potential. In
spite of this depolarization is robust, which suggests redundancy.

5

Figure 1.2: Action potentials in human and mouse ventricular myocytes.
Representation of human (A) and mouse (B) ventricular myocyte APs and ionic
correlates. From Nerbonne[47] reprinted with permission.

What is likely as important as activation of the channels to depolarize the membrane to
cardiac rhythm isthe rate at which the channels recover from fast inactivation. Recovery
from fast inactivation is timed in such a way that, in healthy cardiac tissue, does not allow
for deviations in the normal conduction path. As phase 0 ends and phase 1 begins, Cav
activate and further depolarize the membrane. The L type Ca2+ channel, or Cav1.2, is the
predominate Cav isoform in adult ventricular myocytes[38]. Cav1.2 inactivates slowly
and Ca2+ influx persists through phases 1 through 3 of the AP. Ca v activity is tightly
coupled to sarcoplasmic Ca2+ channels, or Ryanodine receptors (RyRs), which in the
heart, principally consists of the isoform RyR2[39]. E-C coupling requires Ca2+ influx

6

through Cav1.2 that leads to calcium mediated calcium release from sarcoplasmic stores
via RyR2[40, 41].
Phase 1 also denotes the activation of Kv, whose activities persist through phase 4
of the AP. Kv exhibit vast diversity throughout regions of the heart and across species,
with each isoform possessing unique biophysical properties[30]. Kv play a vital role in
shaping the AP; as written by Bertil Hille: "like the stops on an organ, the diversity of
available (Kv) channels is used to give timbre to the functions played by excitable
cells[23]." What Hille is referring to is that the shape and length of the AP is primarily
determined by the activity of each unique Kv isoform and the diverse distribution of Kv
isoforms has important physiological ramifications. For example, in large mammals,
such as humans, ventricular repolarization occurs through two main Kv isoforms: Kv11.1
and Kv7.1 both of which contribute to IKr and IKs current types respectively during phases
2 through 3 of the AP[30, 42]. The activities of these 2 isoforms are characterized by
long sustained K+ efflux allowing the cell to remain depolarized for relatively long
periods of time. The long depolarized state of the cell maintains persistent intracellular
Ca2+ throughout a cycle of contraction. It is this long duration of intracellular Ca2+ that
allows for the robust contractive force necessary in the ventricles of large mammals.
Conversely, the mouse ventricle repolarizes rapidly, which is likely due to a smaller
requirement of contractile force and occurs primarily through the activity of 4 isoforms:
Kv4.2/Kv4.3, Kv1.5 and Kv2.1[43]. Kv4.3 is also found in the human ventricle but is only
responsible for a small fraction of repolarization during phase 1 or the "notch," which
may also consists of a Ca2+ dependent outward Cl- current[42, 44]. In the mouse
ventricle, phases 2 and 3 are less differentiated than in larger mammals and are generally
7

delineated as kinetic components: the rapidly inactivating Ito, which is likely conducted
through the heterotetrameric assembly of Kv4.2/4.3, and the slowly inactivating
components: IKslow1, and IKslow2 which are likely conducted through Kv1.5 and Kv2.1
respectively[43].

The human atria are repolarized primarily through the action of

Kv1.5[45, 46]. Mouse atrial repolarization is well conserved with the ventricle in terms
of the Kv isoforms expressed; however, septal myocytes appear to also express the Kv
isoform responsible for the slowly inactivating transient outward current (Ito,s): Kv1.4 and
repolarization is generally longer lasting in these cells[43]. Kv1.4 is expressed in the
human ventricle and is active during phases 1 and 2[30, 47]. Figure 1.2 details the major
differences in AP waveforms between human and mouse ventricular myocytes as well as
the contributing current types. In addition to differences in Kv isoforms between species
and regions of the heart, individual isoforms can be transmurally expressed. For example
Kv4.3 is more highly expressed in the epicardium compared to the endocardium and the
subsequent current density is higher in that region[48]. The transmural gradient allows
for a physiologic dispersion of repolarization throughout the myocardium[49]. Phase 4
occurs through a wide-range of ion channels and transporters that function to set the
resting membrane potential and to establish ionic gradients across the membrane. These
proteins include inwardly rectifying K+ channels, which function to set the resting
potential[50], as well as proteins that hydrolyze ATP to derive energy for ion exchange
including Na+, K+ and Ca2+- ATPases[51-53]. There are a number of K+ channels where
debate still remains on their exact role in the cardiac AP. This group includes "leak" K+
channels that may contribute to maintaining cellular osmolarity[50], and K(ATP)
channels that are sensitive to intracellular ATP levels and may link metabolism to
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electrical function[54]. A number of these channels are active during other phases of the
AP but their exact contributions are less understood than that of the voltage-dependent
channels mentioned previously. The vast distribution of Kv isoforms throughout the heart
plays a vital role in the repolarization of cardiomyocytes that contributes to E-C coupling
and cardiac conduction. While there are stark differences between the roles of each
isoform in human and mouse cardiac repolarization, the isoforms expressed in both
species are closely homologous. Based on this, the mouse is a useful, although imperfect,
model to study human cardiac electrical signaling[47].
Cardiac conduction occurs via the cable-like coupling of individual myocytes.
Electrical signaling is propagated from cell to cell through low-resistant, large multimeric
protein pores called gap junctions. Each gap junction is formed by the combination of 2
hexameric hemichannels (connexons) assembled from 6 connexin (Cx) proteins[55].
Cardiac gap junctions generally consist of the Cx isoforms Cx40, Cx42 and Cx45, which
demonstrate regional differences in expression[55]. As each myocyte depolarizes, the
electrical signal is propagated from cell-to-cell through gap junctions.

Cardiac

conduction is initiated by a small group of pacemaker cells found in the sinoatrial (SA)
node that contain hyperpolarization activated, cyclic nucleotide-gated (HCN) nonspecific cation channels[56, 57]. HCN along with Kv, and Cav function to produce long
lasting rhythmic depolarizations in the SA node that travel through the atria via the
interatrial tract (Bachman's bundle) or through one of three internodal pathways that carry
the cardiac AP to another pacemaker region: the atrioventricular (AV) node (Fig. 1.3).
The AV node acts as a secondary pacemaker to the SA node and depolarizes at a slower
rate.
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Figure 1.3: Cardiac conduction. Cardiac electrical signaling begins in the sinoatrial
node and follows a discreet pathway through the heart. Figure from Kerwin, 2007
reprinted with permission. http://afibcryoablation.com/types.of.arrhythmia.asp

Conduction travels from the AV node to the His-Purkinje fiber system and then
throughout the ventricular myocardium. Purkinje fiber cells also demonstrate pacemaker
function but are the slowest and considered tertiary pacemakers.

The cardiac AP

propagates through the ventricles from the endocardium to the epicardium leading to the
depolarization of ventricular myocytes. As Nav and Cav inactivate, due to the prolonged
depolarization, the cells enter a period of effective refractory where additional stimulus
has no effect on the cellular AP. As the cell repolarizes, through the action of Kv, it
enters a period of relative refractory where an AP can fire but with a smaller magnitude.
The redundancy in refractory period prevents tetanus, which can occur in skeletal muscle
and neurons, as well as reentrant conduction as a result of ectopic beats.

Cardiac
10

conduction can be observed with electrocardiograms (ECGs) that describe the change in
voltage across the heart as a function of time. The cardiac AP as recorded by an ECG is
the result of electrical activity in each excitable cell of the heart and the coupling of that
activity through gap junctions. The ECG has a number of identifiable features that can
reveal a great deal about the function of the heart (Fig. 1.4). The P wave is the main
electrical vector as it travels from the SA node to the AV node and through the atria. The
QRS complex represents the depolarization of the ventricles. The interval between the
beginning of the P wave and the beginning of the QRS complex describes the time it
takes for the electrical impulse to travel from the SA to AV node. The T wave follows
the QRS complex and represents the repolarization of the ventricles. The time that the
ventricles are depolarized is represented by the ST segment and in healthy hearts is
isoelectric. The interval between the beginning of the QRS complex and the end of the T
wave, the QT interval, is an important indicator of heart health. Shortened and prolonged
QT intervals are arrhythmogenic and may predispose one to sudden death[59-61].

Figure 1.4: Representative electrocardiogram. ECGs demonstrate the change in
voltage across the heart as a function of time. Figure modified from Nerbonne and
Kass[58] reprinted with permission.
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Deviations in normal cardiac electrical activity, or arrhythmias, affect at least 5
million people in America and contribute to the mortality of at least 400,000
annually[62]. Arrhythmias have diverse etiologies and are typically characterized by the
location in the heart where they occur and the type: tachycardia (speeding up of the heart
beat), bradycardia (slowing of the heart) or block, where the electrical impulse
(conduction) cannot travel through its normal pathway. Changes in pacemaker activity
play a large role in the genesis of arrhythmias and can be described by a change in rate,
or more dangerously, by the formation of ectopic pacemaker activity. A prolonged
depolarization can cause atrial and ventricular myocytes to act as pacemakers. This
occurs because Nav are inactivated but Cav and Kv are still functioning. The prolonged
depolarization can allow Cav to recover from inactivation and re-activate. The result is a
depolarization that occurs during phase 2 or 3 of the AP [early after depolarization
(EAD)]. Additionally, during phase 4 of the AP, persistent cytosolic Ca2+ can activate
the sodium calcium exchanger causing a depolarizing current and a delayed after
depolarization (DAD). Successive DADs can cause extra systoles, which may lead to
ventricular tachycardia and potentially to the rapid and chaotic contraction of the
ventricles (fibrillation).
intervention.

Ventricular fibrillation is life-threatening without medical

The impedance of cardiac conduction (conduction block) along with

ectopic pacemaker activity may contribute to reentrant conduction (reentry). Reentry is
characterized by conduction loops and can lead to fibrillation of the atria and ventricles.
An ECG is an important indicator of cardiac electrical health; however, it does not
always elucidate the etiology of an arrhythmia. For example, a lengthening of the QT
interval [long QT (LQT)] and Brugada syndrome, which has 3 unique ECG patterns, can
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both be caused by any number of acquired or congenital pathologies[63, 64]. There is an
array of diseases that were linked to arrhythmias including high blood pressure, diabetes,
coronary artery disease and myocardial infarction and ischemia[65-68]. Many of these
diseases lead to structural changes in the heart such as hypertrophy or scarring that can
impact conduction outflow. Not surprisingly, pathological changes or differences in Nav
and Kv function significantly impact cardiac function and arrhythmogenesis. Congenital
defects in VGIC genes of otherwise healthy individuals cause arrhythmias[69]. As an
example, there are a number of conserved mutations in the human Nav1.5 gene that are
responsible for both Brugada syndrome as well a LQT type 3(LQT3)[70]. Additionally,
mutations in the Kv11.1 gene (hERG) can cause both LQT and short QT (SQT)
syndromes[71, 72]. Kv11.1 is also an important mediator in drug-induced LQT syndrome
so much so that every drug that is released in the U.S. must be tested
electrophysiologically for reactivity with the hERG gene product. Nav and Kv mediated
arrhythmias occur as a result of other acquired etiologies. Diseases that cause heart
failure or structural changes such as hypertrophy are, in and of themselves, proarrhythmic.; however, there may be secondary effects that specifically alter VGIC
expression and function, which exacerbates the condition. Human cardiac hypertrophy is
associated with a decrease in Ito and LQT[73]. Animals models of pressure-overload
cause changes in Kv gene expression and can abolish the transmural expression of
Kv4.3[74-78].

Pressure-overload models have also demonstrated an effect on Nav

expression and INa characteristics[79-81].

Heart failure and hypertrophy can cause

activation of the renin-angiotensin-aldosterone-system (RAAS). Activation of RAAS is
at first compensatory but becomes pathological through chronic stimulation. RAAS
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decreases Ito in experimental models[82, 83] and can increase INa and voltage-gate Ca2+
current (ICa)[84-87]. Diabetes is associated with a down-regulation of Ito and a shift in Kv
isoforms in human and animal models[66, 88, 89]. Unusual cardiac activation itself, such
as tachycardia, can also cause changes in VGIC expression/function[90, 91]. Overall,
alterations in VGIC expression contribute to remodeling and are important mediators in
arrhythmogenesis. Cardiac conduction includes the concerted actions of all ion channels
and transporters, including VGICs, in an individual cell as well as specific regions of the
heart. While some redundancy exists, without the proper density and function of all
channel types, the susceptibility to re-entrant current and arrhythmias is greatly increased.

1.3. Excitability is influenced by di- and multivalent ionic species
The studies of Hodgkin, Huxley and Katz during the 1940s and 50s, using the
axon of giant squid, imparted important principals to the understanding of cardiac
electrical signaling. The ideas that cells are selectively permeable to ionic species and
that ionic flux is dependent on voltage changes are vital to understanding cardiac
physiology. The studies were prologue to how biophysical approaches could be used to
investigate the function of the heart including the role of electrostatic interactions and
electrical driving force. These methods can be utilized as they are in ECG recordings to
observe cardiac activity as well as to offer insight into pathological changes in function.
As in example many patients that suffer from ionic imbalances, such as hyper- or
hypocalcemia, show signs of altered electrical activity including arrhythmias, ECG
abnormalities, paralysis and tetany[92-94]. Interestingly, in a study reported five years
following the initial Hodgkin and Huxley reports using the axon of squid,
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Frankenhaeuser and Hodgkin observed that when the extracellular Ca2+ concentration
[Cao2+] was increased, cellular excitability decreased (Fig. 1.5)[95]. A number of studies
followed the Frankenhaeuser and Hodgkin report of the dampening effect of increased
[Cao2+] and regardless of the channel or tissue type studied, the same type of decrease in
VGIC activity was observed[23, 96-109]. In many of the studies, other divalent or
multivalent cations were used to produce similar effects.

The data often showed a

uniform, rightward shift in all voltage-dependent gating parameters.

Figure 1.5: External Ca2+ shifts VGIC activation voltage. Decreased external [Ca2+]
results in a 10-30 mV shift in squid giant axon Na+ current activation voltage. From B.
Frankenhaeuser and A.L. Hodgkin[95] reprinted with permission.
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Despite investigations into the effect of increased divalent cation concentration on
cellular excitability proceeding long after the experiments performed by Frankenhaeuser
and Hodgkin, it was a suggestion by their colleague A.F. Huxley following those initial
studies that offered the first and most prevailing explanation of the phenomenon. As
stated in the Frankenhaeuser and Hodgkin work[95], Huxley proposed, “that calcium ions
may be absorbed to the outer edge of the membrane and thereby create an electric field
inside the membrane which adds to that provided by the resting potential.” It was this
suggestion that would develop into what is known as the surface potential theory, a
theory that would help shape the manner in which VGIC gating was studied in the years
to come[23].

1.4. Surface potential theory predicts external negative surface charge contributes to
channel gating
VGICs are transmembrane proteins that must be partially soluble in an ion-rich
aqueous environment. Their solubility depends on the presence of significant numbers of
polar or ionized functional groups on the channels or in close proximity to them. The net
electric field created by the various ionic groups arranged across or near the membrane
influences the resting membrane potential. The fundamental principal of the surface
potential theory is defined by this phenomenon. Consistent with the dampening effect
imposed by increased [Cao2+] on excitability, extracellular negative surface charges
contribute to the surface potential and thereby to the membrane potential[23, 102, 110113]. Because of the nature of cellular membranes and the distribution of polar and
ionized functional groups throughout them, there may be a great deal of heterogeneity in
16

the spatial arrangement and magnitude of the negative surface charge[114, 115].
Biophysicists utilized models created by Louis Georges Gouy and David Chapman
(Gouy-Chapman model) to study hypothetical planar surfaces bearing a uniform charge
immersed in a salt solution in order to quantify the membrane surface charge[116, 117].
However, the Gouy-Chapman model only considered the charge of the ionic species and
did not take into account potential chemical interactions of the electrolytes in the solution
and molecules fixed to the membrane[116-118]. Later, the Stern modification was added
to the Gouy-Chapman model to take into account the potential binding of molecules
including the reversible interaction between acidic groups and protons or metal
cations[118, 119]. Based on the Gouy-Chapman-Stern model, one can predict that when
the extracellular solution is high in cations particularly di- or multivalent species, the
negative surface charge will be masked or shielded, thus abolishing the contribution of
the negative surface charge to the membrane potential.

The observations of

Frankenhaeuser and Hodgkin and those who followed describing the effect of increased
cations and the subsequent decrease in excitability can be explained by the shielding (and
perhaps, binding) of negative surface charge which would essentially act to hyperpolarize
the membrane compared to when the negative surface charge was free to exert its effect
on the membrane potential (see figure 1.6 and Hille, 2001[23] for details).

1.5. What contributes to the negative surface charge?
One major source of ionic species in a membrane is the phosphate head groups of
the phospholipid bilayer.
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Figure 1.6: External net negative surface potential impacts membrane potential
sensed by VGIC. Illustration of the putative effects of external negative charges on the
electric field and resulting membrane potential. Surface potential theory predicts that
increases in external divalent cations nullifies the impact of the surface charge on
membrane potential. Figure from B. Hille [23] page 650 reprinted with permission.

McLaughlin et al. demonstrated that phospholipids bathed in a salt solution have surface
potentials ranging from -40 to -120 millivolts (mV). Interestingly it was calculated that
the local [Ca2+] was as much as 104 times greater at the surface of the bilayer compared
to the rest of the solution[111, 120-123].

Later, the effect of negatively charged

membrane phospholipids on Nav activity was investigated directly by expression of the
channel in lipid bilayers that either contained phosphate groups or did not. It was
determined that in the presence of higher (7.5 mM) [Cao2+], the half activation voltage
(Va) was shifted rightward by 17 mV in the neutral bilayer and by 25 mV in the
negatively charged bilayer[124].

The data suggested that negatively charged

phospholipids contribute to the surface potential, and based on the relative shifts in Va in
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the presence of high [Cao2+], it is reasonable to assume that external negative charges
other than phospholipids had a greater impact on Nav gating than did the charged bilayer.
As the sequences and structures of VGICs were uncovered, a number of studies
provided a possible explanation for the apparent additional sources of negative surface
charges. Elinder and Arhem detailed a common motif of acidic amino acids in a key
extracellular location on multiple Kv isoforms. They proposed that the depolarizing shift
in the voltage dependent properties of Kv caused by increased divalent cation
concentrations was due to charge shielding of glutamate and aspartate residues found on
the loop between the fifth transmembrane segment (S5) and the pore helix[109, 125-127].
Elinder and Arhem’s hypothesis offered a quantifiable explanation of the apparent
additional surface charge found on VGICs.

They did not however consider the

contribution of other charged molecules.
In the early 1980s a number of studies were performed investigating the
tetrodotoxin (TTX) sensitivity of Nav in the electric eel electrophorus electricus. It was
discovered that the binding of TTX occurred on the channel itself[128] and through
biochemical analyses, that the Nav were extensively modified by extracellular
glycosylation, up to 30% of the total channel weight[128-130].

In subsequent

experiments utilizing enzymes that recognize and cleave specific carbohydrate residues,
it was determined that a large proportion, as many as a 100 residues, consisted of the
carbohydrate derivative N-acetylneuraminic acid or sialic acid[131, 132]. Sialic acids
belong to a group of 9 carbon chain sugar molecules in which many are substituted with
an acetylated amine group at C5 and a carboxylic acid that is deprotonated and negatively
charged at physiological pH at C1[133]. Those who first discovered the unusually high
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levels of negatively charged sugars attached to the Nav of electric eels were likely
intrigued by the potential contribution of sialic acids to the surface potential and to VGIC
function.

1.6. Glycosylation is a sequential process
As synthesis of a nascent integral membrane protein such as a VGIC begins, it is
quickly recognized by a signal sequence of specific nonpolar amino acids located in the
N-terminus that targets it for translocation into the endoplasmic reticulum (ER)[134].
Translation continues with the ribosome attached to the ER and the growing protein
inserted further into the lumen. Translocation of a protein into the ER is required for
subsequent trafficking of the protein and for the necessary protein processing including
glycosylation, which occurs on essentially every integral membrane or secretory
protein[135]. Extracellular protein glycosylation occurs through two mechanisms: 1) Nglycosylation, in which an N-acetyl glucosamine (GlcNAc) is covalently bonded to an
asparagine residue that serves to initiate a three amino acid consensus N-glycosylation
sequence that consists also of any second amino acid, except proline, and ends with a
serine or threonine residue (NXS/T)[137] or or 2) O-glycosylation that involves the
covalent addition of an N-acetyl galactosamine (GalNAc) to a serine or threonine without
any other known sequence requirements[138], although recent studies suggested
“permissive” sequences[139, 140]. In the case of N-glycosylation (Fig. 1.7[136]), when
the NXS/T sequence is recognized by specific enzymes located in the ER, a block of 14
simple carbohydrates is transferred to the growing protein from a dolichol phosphate
molecule donor consisting of 20 isoprene units attached to the luminal wall of the
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ER[141, 142].

Thus, N-glycosylation can be more accurately described as a co-

translational modification as opposed to its usual moniker of a post-translational
modification at least for the initial steps of the process. The en bloc carbohydrate
structure, consisting of two GlcNAcs, nine mannoses and three glucose residues, is
processed by removal of all three glucose residues in a sequential manner[143]. In many
primitive species the high mannose structure is the final glycan structure; however, in
more sophisticated organisms, N-linked glycosylation continues in the distal ER and
Golgi with the formation of more complex glycan structures beginning with mannose
trimming through mannosidase activity (Fig. 1.7)[137, 143]. O-linked glycosylation does
not require the en bloc addition of multiple sugar residues. Only a single GalNAc is
required for initiation, which is added in the ER; all further glycosylation is thought to
occur in the Golgi[137, 139].

Figure 1.7: Extracellular glycosylation is a sequential process that occurs in the ER
and Golgi and involves the activity of hundreds of glycogene products. Illustration of
the process of protein N-glycosylation as it occurs in the ER and Golgi. Figure from A.
Helenius and M. Aebi[136]. Reprinted with permission from AAAS.
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Following initiation of both N- and O-glycosylation, additional carbohydrate
residues are added in a regulated and sequential manner as the protein travels through the
cis, medial and trans cisternae of the Golgi.

Enzymes, referred to as

glycosyltransferases, add sugars from carbohydrate-nucleotide donors to their substrates
with specific covalent linkages[144], which in many cases can form large multi-antennae
carbohydrate branches. Glycosyltransferases are localized in different regions of the
Golgi; therefore, the type and amount of sugars that are added to the glycan structures
depends on where the nascent proteins leave the Golgi complex and on the relative
expression/location of the glycosyltransferases[145], which, as will be discussed in more
detail in the following sections, can differ among cell types and species[146]. More
recently there are reports of glycosyltransferases that function in the cytoplasm and at the
plasma membrane, which would increase the ability of a cell to augment glycosylation
and perhaps even alter it in response to certain stimuli[137]. In addition, there are a
variety of glycosidases responsible for removing certain sugar residues by cleaving
specific linkages[147-150].

1.7. The terminal residues attached to glycans are sialic acids
Many complex carbohydrate branches terminate with the addition of sialic acids
through the activity of various sialytransferases. Sialic acids can demonstrate striking
structural variability with approximately 50 known isomers[151] although common to
almost all is a negative charge at physiological pH originating from a deprotonated
carboxylic acid that, while dependent upon the other substituted side groups, possesses a
pKa of approximately 2.6[152]. Sialytransferases also demonstrate great variability.
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Presently there are 20 different cloned mammalian sialytransferases that are organized in
four groups by their substrate and linkage specificity: β-galactoside α2,3, β-galactoside
α2,6, GalNAc α2,6 and α2,8[153].

The α2,8 group of sialytransferases are

polysialytransferases that can link polymers of sialic acids to a single sialic acid residue,
leading to the formation of large, complex and heavily sialylated proteins. For example,
in addition to the approximately 100 polysialic acids found on the Nav of E. electricus
mentioned previously, there are reports of neuronal cell adhesion molecules (NCAM)
with as many as 200 polysialic acid residues attached[132, 154]. Data suggest that sialic
acid processing can continue at the membrane surface; a family of endogenous sialidases
were identified that can remove sialic acids from transmembrane proteins although the
purpose and mechanisms of these enzymes are poorly understood[155, 156]. Further, in
certain cell types, extracellular sialyltransferase activity may create the potential for the
dynamic regulation of protein sialylation[157-160].

Collectively, the process of

glycosylation provides an opportunity for great diversity in glycan structures and levels
and types of attached sialic acids, leading to the potential for a large and variable deposit
of negative charge located on the external surface of the plasma membrane.

1.8. Role of glycans in cellular communication
Genes involved in glycosylation (glycogenes) represent 1-2% of the mammalian
genome and function to create a wide range of glycan structures unique to individual
organisms[161].

Cell and species recognition depends on the specificity of glycan

structures which function as a molecular component of cellular communication. Such
communication serves many physiological purposes including immune responses to
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exogenous and endogenous pathogens, receptor activation, cell adhesion, endocytosis and
molecular trafficking. While deficiencies or alterations in glycosylation generally do not
produce significant phenotypes in vitro, diseases of glycosylation lead to serious
morphological, functional and developmental deficits clinically and in mouse
models[161]. One family of diseases known as the congenital disorders of glycosylation
(CDGs), which includes ~ 40 different isotypes, can affect both N- and O- linked
glycosylation and is caused by congenital defects in glycogenes resulting in
hypoglycosylation[162]. The mutated glycosylation structure(s) vary among CDG, but
reduced glycoprotein sialylation is common to nearly all. CDGs can lead to severe
defects in many of the body’s systems, particularly the nervous[163, 164] and
cardiovascular[165] systems, and many forms of the disease lead to a high prevalence of
infant mortality[166]. Additionally, muscular dystrophies, which many include in the
family of CDGs, cause impairments in neuromuscular development and function[167].

1.9. How does sialic acid modulate voltage-gated Na+ channel activity?
It did not take long following the discovery that Nav from E. electricus were
heavily glycosylated and more specifically heavily sialylated to question if the negatively
charged sialic acids played a physiological role in the activity of the channel. In 1990
Recio-Pinto et al. expressed the purified channel in lipid bilayers and found that when the
protein was treated with the glycosidase neuraminidase, which cleaves sialic acid
residues, significant depolarizing shifts in voltage dependent channel activation were
observed[168]. At the time, it was difficult to determine whether the change in channel
function caused by desialylation was due to a change in protein structure and stability or
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was specifically related to the decrease in negatively charged sialic acids. Further, the
bilayer studies required treatments to limit Nav inactivation, thus preventing the complete
assessment of channel gating ± sialic acids. Based on the studies by Frankenhaeuser and
Hodgkin and others, the surface potential theory was put forth as a potential mechanism.
It seemed apparent that such a large deposit of negative charge located somewhere near
the external surface of the membrane (although this is not known) might impact the
activity of VGICs.

Indeed 15 years later, a study utilizing a number of rigorous

biochemical techniques demonstrated that the removal of sialic acids from Nav caused no
significant effect on channel structure or stability and that the effect of sialic acids on
channel function was strictly mediated through electrostatic interactions[169]. In 1997,
Bennett et al. demonstrated similar effects of desialylation on the activity of mammalian
skeletal muscle Nav (rSkM1, or Nav1.4) expressed in Chinese hamster ovary (CHO) cells
using three independent methods to reduce channel sialylation.

Figure 1.8: Reduced sialylation of the skeletal muscle Nav through three
independent methods produced nearly identical shifts in all voltage-dependent
gating mechanisms. Conductance-voltage (G-V) relationships for Nav1.4 expressed
under conditions of full sialylation (+SA) and three independent conditions of reduced
sialylation (-SA; neuraminidase-treated, to remove sialic acids (left), in the essentially
non-sialylating Lec2 cell line (middle), and two deletion mutants in which four or five Nglycosylation sites were removed (right). Adapted from E .Bennett et al.[170] reprinted
with permission.
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Enzymatic removal of sialic acids, expression of the channel in a sialylation-deficient cell
line (Lec2[171, 172]) and deletion of a 24 and 30 amino acid region of DIS5-S6 that
contained four and five putative N-glycosylation sites, respectively, led to similar
depolarizing shifts in all voltage-dependent properties of the channel (Fig. 1.8) [170].
Additionally, the depolarizing shifts in channel gating caused by increased divalent cation
concentration were ameliorated significantly in the absence of sialic acids indicating that
sialic acids contributed to the dampening effect of increased divalent cations on
excitability (Fig.1.6). This phenomenon demonstrates the principal behind the surface
potential theory and how it relates to sialic acids; that is, the presence of extracellular
negatively charged molecules (sialic acids) causes the membrane around the channel to
be slightly depolarized. The local, slight depolarization primes the VGIC requiring a
smaller change in membrane potential to induce channel gating. When the extracellular
solution is high in di- or multivalent cations, the negative charges of the sialic acids are
likely shielded through electrostatic and molecular interactions as described by the GouyChapman-Stern model. The initial studies investigating the effects of sialic acids on Nav
activity provided a striking example of how protein processing can lead to sophisticated
forms of regulation on not only the specialized Nav found in the electric eel but also on
mammalian isoforms.

1.10. The effect of sialic acids on Nav gating is dependent on the specific Nav isoform
Nearly all VGIC isoforms are uniquely glycosylated. For example, up to 30% of
the mature molecular mass of the Nav isoforms found predominately in skeletal muscle
and neurons are comprised of sugar residues, while the primary Nav isoform found in
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cardiac tissue (Nav1.5) is reported to be approximately only 5% carbohydrate[173]. Such
diversity among isoforms may arise from the differences in the number/location of
glycosylation sites (glycosylation signatures) on the different isoforms and/or the extent
of glycosylation that occurs in the Golgi. Considering the differences in glycosylation
levels and gating properties of the various Nav isoforms and following the initial
observation that rSkM1 activity was regulated by sialylation, potential isoform-specific
effects of glycosylation on different Nav was questioned.

In 1999, Zhang et al.

investigated how reduced sialylation differentially affects rSkM1 and the human cardiac
Nav1.5 (hH1A)[174]. Reducing sialylation of hH1A depolarized the Va by 9 mV and
depolarized the mid-point of the steady-state inactivation (SSI) curve and the voltage of
half-inactivation (Vi), by 12 mV. Reduction in the levels of sialic acid on rSkM1 caused
an 8 mV depolarizing shift in activation and a 4 mV hyperpolarizing shift in SSI, which
was the first report of a hyperpolarizing shift in VGIC gating caused by a reduction in
negative surface charge. In 2002, the effects of reduced sialylation on the human skeletal
muscle Nav (hSkM1; Nav1.4) and hH1A were investigated utilizing CHO cells[175]. The
study reported that desialylation of hSkM1 led to 11-15 mV depolarizing shifts in
conductance-voltage (G-V) and SSI relationships as well as in the Va, Vi, the rate of fast
inactivation and the rate of recovery from fast inactivation. There were no changes in the
gating parameters of hH1 following desialylation. Immunoblot analyses indicated that
both channels are glycosylated but hSkM1 possesses greater levels of glycosylation and
sialylation. Electrophysiological recordings in the presence of high [Cao2+] suggested
that sialic acids altered hSkM1 gating thorough electrostatic interactions. Chimeras were
created in which the heavily glycosylated DIS5-S6 loops of hSKM1 and hH1 were
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exchanged (creating, hSkM1P1 and hH1P1, respectively).

Simply by replacing the

hSkM1 DIS5-S6 loop with the hH1 DIS5-S6 loop, the voltage-dependent gating of
hSKM1P1 was unaffected by changes in sialylation. However, gating of the converse
chimera, in which the hH1 DIS5-S6 loop was replaced with the hSKM1 DIS5-S6 loop
(hH1P1) was modulated by changes in channel sialylation. That is, a switch in gating
phenotype from sialic acid sensitive to insensitive (and vice-versa) was achieved by
swapping the DIS5-S6 loops between two Nav isoforms that were differently sensitive to
changes in channel sialylation. These data suggested that the sialic acid residues relevant
to modulation of Nav gating were localized to the DIS5-S6 loop.
In a study by Johnson et al. in 2004, the gating of four different Nav isoforms was
investigated[176].

Consistent with the previous report[175], the more heavily

glycosylated Nav1.4 demonstrated the largest depolarizing shifts in gating midpoints
following desialylation, while NaV1.5, which is apparently the least glycosylated Nav
isoform, was unaffected by desialylation as expressed in CHO cells. Two neuronal Nav
isoforms Nav1.2 and Nav1.7, which are moderately glycosylated in relation to Nav1.4 and
Nav1.5, displayed correspondingly moderate depolarizing shifts in gating midpoints
following desialylation.

The results of this study suggested a dose response like

relationship between the levels of sialylation and the observed effects on channel gating;
this is discussed in more detail later. Together, these data suggest that the glycosylation
of Nav affects function in an isoform specific manner and, based on the discrepancy in
results observed between the Satin and Bennett groups[174-176], that desialylation can
affect the same Nav differently depending on the cell type in which the isoform is
expressed. Satin’s group expressed the cloned channels in human embryonic kidney
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(HEK) cells while the Bennett group utilized CHO cells. Both findings imply that some
of the biophysical properties that differentiate VGICs may be due to differing levels of
glycosylation and that the process of glycosylation is regulated and dependent on the type
of cell where the glycosylation occurs. This idea of cell-specific regulated glycosylation
was later investigated and supported by several studies that will be discussed in more
detail in a later section[177-179].

1.11. Sialic acids attached to heavily glycosylated Nav β subunits impact Nav α
subunit gating
The α or pore forming subunit of Nav, like other types of VGICs, typically
interact with various auxiliary or β subunits. In many cases, β subunits are vital to the
correct trafficking and insertion of the α subunits and can modulate conductance and
gating[180-182]. A number of studies indicate that when Nav α subunits are co-expressed
with β subunits, channel activity is altered in an isoform and stoichiometric dependent
manner[182, 183]. Nav β subunits are transmembrane glycoproteins. In 2004, Johnson et
al. demonstrated that co-expression of the fully sialylated β1 isoform caused a
hyperpolarization of the G-V and SSI relationships of Nav1.5, Nav1.2 and Nav1.7[176].
The presence of β1 had no effect on gating of the heavily sialylated Nav1.4. Additionally,
the fully sialylated β1 subunit increased the rate of fast inactivation and slowed the rate of
recovery from fast inactivation for Nav1.5, Nav1.2 and Nav1.7. The hyperpolarizing
effect of the β1 subunit on Nav α subunit gating was abolished under conditions of
reduced sialylation, suggesting that β1 sialic acids were responsible for the modulatory
effect of β1 on Nav1.5, Nav1.2 and Nav1.7 gating. Further, the authors prevented N29

glycosylation of β1 through mutation of all four putative N-glycosylation sites. This
proved sufficient to prevent any effect of β1 on gating of the Nav α subunits. Together,
these data indicated that β1 subunit modulation of Nav1.5, Nav1.2 and Nav1.7 was
mediated fully through β1 sialic acids imposing a hyperpolarizing effect on α subunit
voltage-dependent gating. To help determine whether the modulatory effect of β1 sialic
acids was due to an electrostatic mechanism, gating of the fully sialylated Nav α subunit,
when co-expressed with β1, was the most sensitive to changes in [Cao2+], suggesting that
β1 sialic acids contribute to the surface charge that impacts Nav α subunit gating.
Interestingly, when the glycosylation levels of the heavily glycosylated Na v1.4 (that was
unaffected by β1 co-expression), were reduced through construction of the hSkM1P1
chimera, fully sialylated β1 co-expression caused a hyperpolarization of the G-V and SSI
relationships, mimicking the effects of β1 on the Nav1.5, Nav1.2 and Nav1.7 isoforms.
These data suggested that the impact of sialic acids on Nav gating is an additive and
saturating phenomenon involving α and β subunit sialic acids.
In a later study, Johnson and Bennett investigated whether the β2 isoform affected
Nav1.5 and Nav1.2 gating[184]. The study reported that β2 co-expression caused a sialic
acid dependent hyperpolarizing shift in Nav1.5 gating but not in Nav1.2 gating.
Additionally, when β1 and β2 were expressed together with Nav1.5, the two β subunits
acted synergistically to cause an additive sialic acid dependent hyperpolarization of
Nav1.5 gating. Previous to these two studies, the effect of sialylation on Nav function was
attributed only to sialic acids found on the α subunits. The data obtained investigating
the effects of β1 and β2 on Nav1.4, Nav1.5, Nav1.2 and Nav1.7 were the first to show that
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auxiliary subunits could also contribute to the surface potential experienced by Na v, and
do so through apparent saturating β subunit-specific mechanisms.

1.12. Sialic acids have a similar effect on Kv activity
Concurrent with the studies investigating Nav glycosylation, the functional effects
of glycosylation and sialylation were also being investigated on Kv. In 1996 Thornhill et
al., observed that the rat Kv1.1 isoform was functionally affected by sialylation. The
removal of sialic acids using neuraminidase, expression of the channel in the sialylationdeficient Lec2 cell line or a CHO cell line in which glycoproteins and glycolipids are
missing the terminal galactose and sialic acid residues, (Lec8)[172, 185], shifted the Va to
more depolarized potentials and slowed the kinetics of the channel in an electrostatic
dependent manner[186].

Later, single channel analysis of Kv1.1 indicated that the

depolarizing effect of desialylation on the gating of macroscopic currents was similarly
observed at the single channel level as described by an 8mV depolarized shift in the
fractional open time (fo) and a shallower fo-voltage slope of a glycosylation deficient
Kv1.1 mutant compared to the wild type with no observed change in the maximal
conductance[187]. Kv1.1 and Kv1.2 are homologous Kv isoforms found predominately in
the brain and shown to possess sialic acid-rich glycan structures[188, 189]. In 2007 the
role of sialylation in Kv1.2 function was investigated through a novel approach; that is,
previous studies investigating the effects of VGIC sialylation were performed by
reducing the levels of sialic acids or exchanging the functionally relevant glycosylation
sites with those of more heavily glycosylated isoforms[190]. In this study, mutants were
created where glycosylation sites were added to the channel and compared to the function
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of the wild type channel. Addition of two N-linked sites to Kv1.2, giving the channel a
total of three sites, caused the Va to be hyperpolarized by 5mV, steepened the slope of the
G-V relationship and increased the rate of activation and inactivation. An additional
mutant was created that lacked the single putative N-linked glycosylation site.
Subsequent experiments on the N-linked deficient mutant demonstrated a depolarizing
shift in Va, a broadening of the slope of the G-V curve and decreased channel kinetics.
The effects of altered sialylation on channel function were sensitive to increased divalent
cation concentration.
In 2008, Johnson and Bennett observed that gating of the Drosophila shaker KV,
ShB, was depolarized under conditions of reduced sialylation[191]. The group went on
to show that the contribution of sialic acids to the channel’s function was likely mediated
through an electrostatic mechanism.

Interestingly, only recently was it shown that

Drosophila sialylates proteins[192]. Subsequent studies were performed on other Kv
isoforms and demonstrated that, similar to its effects on Nav activity, sialylation
modulates Kv function in an isoform specific manner. A 2001 study by Ufret-Vincenty et
al. indicated that the Kv isoforms (likely, Kv4.2/4.3[193]) responsible for Ito,f in the adult
mouse heart were affected by desialylation[194]. A depolarizing shift in activation and a
decrease in current density of Ito,f were observed following neuraminidase treatment of
adult mouse ventricular cardiomyocytes. In the same study, recombinant Kv4.3 was
expressed in the fully glycosylating parental CHO cell line and the sialylation-deficient
Lec2 line, with data indicating a similar depolarizing effect on voltage dependent
activation of Kv4.3 expressed in Lec2 cells. Ufret-Vincenty et al. also questioned the
possible contribution of sialylated lipids to the surface potential finding that the sialic
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acids that had the most prominent effect on KV4.3 function were those found on
glycoproteins (likely the channel itself) and that sialylated glycolipids did not
significantly affect channel activity.

In 2010, Schwetz et al. showed that voltage

dependent activation but not inactivation of Kv1.5 was shifted to hyperpolarized
potentials by sialic acids through electrostatic mechanisms. However, Kv1.4 was not
similarly affected by sialylation (at least in CHO cells)[195].

1.13. Sialic acids linked to O-glycans also modulate VGIC gating
Recently, Schwetz et al. investigated the effect of sialylation on the
heterologously expressed Kv isoforms Kv2.1, Kv4.2 and Kv4.3[196].

As mentioned

previously, protein glycosylation occurs in either an N- or O-linked manner and because
of the complexity and lack of a consensus O-linked sequence, prior studies investigating
the effects of sialic acids on VGIC function were limited to N-linked glycosylation or
generic sialylation. Kv4.2 and Kv4.3 possess no N-linked glycosylation sites and while
Kv2.1 does possess a single N-linked site, based on recent structural data, it is highly
unlikely that it is N-glycosylated[197, 198]. The report indicated that reduced sialylation
depolarized the G-V curves and Va by 16, 8 and 9 mV for Kv4.2, Kv4.3 and Kv2.1,
respectively, but had no effect on SSI. Electrophysiological experiments were repeated
in the presence of high extracellular Ca2+ and indicated that the effect of reduced
sialylation was mediated through electrostatic mechanisms. Biochemical experiments
utilizing glycosidase gel shift analyses and Click chemistry[199] demonstrated that none
of the three isoforms were N-glycosylated but all were O-glycosylated and sialylated,
indicating for the first time that O-linked sialic acids impact VGIC function.
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1.14. Sialic acids modulate VGIC gating through subunit-specific mechanisms
Gating of VGICs are altered by sugars attached to channels in an isoform-specific
manner, likely due to each isoform’s (and/or auxiliary subunit’s) unique set of potential
glycosylation sites, or the glycosylation signature. Most studies established that the
sugar-dependent gating effects were imposed by the terminal residues attached to N- and
O-glycans, sialic acid. Often, an electrostatic mechanism was assigned with negatively
charged sialic acids contributing to a surface potential, causing channels to gate at less
depolarized potentials. With the regulated expression of VGIC α subunit isoforms, each
with their unique glycosylation signature, together with various combinations of auxiliary
subunits that are each uniquely glycosylated, gating of VGICs can be modulated through
subunit-specific differential sialylation that can potentially alter channel function through
multiple mechanisms.

1.15. Data suggest that cellular environment may impact how sialic acids modulate
channel gating
The effect of sialic acids on VGIC function appears to be determined, at least in
part, by the cell type in which the glycosylation occurs.

As described above, the

glycosylation process is complex, with the activity of hundreds of glycogenes responsible
for channel glycosylation. Thus, the presence and/or activities of the glycogenes are
likely regulated and different among cell types, and this will determine the types and
levels of glycans attached to expressed proteins.

For example, independent studies

investigating the glycosylation of two different proteins expressed in either CHO or HEK
cells indicated significantly greater levels of glycosylation attached to proteins expressed
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in CHO cells[200, 201]. The study also showed increased total CHO cell sialylation and
different sialic acid linkages between the two cell lines[201]. These data offer a possible
explanation for the apparently conflicting results between the Satin and Bennett groups
where the former observed significant changes in the voltage dependent properties of
Nav1.5 under conditions of reduced sialylation while the latter only observed a change in
gating when Nav1.5 was expressed with β subunits[174-176]. Additionally, Zhang et al.
observed a hyperpolarizing shift in SSI of Nav1.4 while the Bennett groups observed a
marked depolarizing effect of desialylation on Nav1.4 SSI. It is interesting to consider
that perhaps the differences in sialic acid linkages occurring in the CHO and HEK cells,
as observed by Suen et al., or perhaps differences in overall activity of sialytransferases
between the two cell lines, may also contribute to surface charge based on the spatial
configuration of extracellular sialic acids.

This idea of cell-specific effects of

glycosylation on channel function is further supported by comparing the data obtained
using expression systems to that observed from studies investigating the sialylationmediated effects on Nav1.5 gating in native cardiac myocytes. First, Ufret-Vincenty et al.
indicated that enzymatic removal of sialic acids from adult mouse ventricular myocytes
caused a depolarization of Va and hyperpolarized SSI[202]. Secondly, the Bennett lab
showed in one report that sialic acids attached to Nav1.5 expressed in CHO cells had no
effect on channel gating, while, in a second report showed that Nav1.5 expressed in
neonatal and adult atria as well as in adult ventricles (but not in neonatal ventricles), was
sensitive to desialylation[177, 178]. In 1999, Shi and Trimmer described an isoform
specific effect on Kv glycosylation when comparing native and heterologously expressed
channels[188]. Additionally in two similar studies, natively expressed neuronal Kv were
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also shown to be differentially glycosylated and uniquely sialylated. A report in 2008
demonstrated that the KV isoforms 3.1, 3.3 and 3.4 show variation in the levels and
perhaps types of glycan structures attached to each isoform that was dependent on the
brain region from which the proteins were isolated[203]. This included the spinal cord,
hypothalamus thalamus, cerebral cortex, hippocampus, and cerebellum of adult rats. A
subsequent study in 2009 by Cartwright and Schwalbe demonstrated that Kv3.1, Kv3.3,
Kv3.4, Kv1.1, Kv1.2 and Kv1.4, isolated from adult rat brains, all contained significant
levels of sialic acids[189]. It was also determined that the Kv3 proteins contained α2,3
and atypical α2,8 sialyl-linkages and that at least one of the multi-antennae glycan
structures possessed sialic acid polymers. Contrastingly, the Kv1 isoforms had only α2,8
sialyl-linkages.

Both families of Kv isoforms had sialic acids linked to internal

carbohydrate residues, which was previously only thought to occur on gangliosides. The
authors suggested that the presence of these atypical sialic acid linkages would play a role
in “modulating and fine tuning the excitable properties of neurons in the nervous
system.” Collectively the described observations suggest that glycosylation is regulated,
which is an important phenomenon that will be expanded upon in the proceeding
sections.

1.16. The extent of channel sialylation is apparently cell-specific and changes during
development
The majority of data discussed thus far concerning VGIC sialylation originated
from studies utilizing recombinant proteins expressed in immortalized cell lines or lipid
bilayers. These data described important functional consequences of VGIC sialylation
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and provided insight into the probable electrostatic mechanism by which sialic acids
modulate VGIC gating. Additionally, the previously described studies introduced the
notion that channel activity is modulated differently depending on the type of cell in
which the protein is expressed; this is likely linked to the types and levels of sialylation
that occur differentially among cell types. How do these phenomena translate to native
biological systems and whole organism physiology? In 2001, Tyrrell et al. reported that
the glycosylation state of Nav1.9 changes between neonate and adult rat dorsal root
ganglia (DRG) neurons[179]. Western blotting indicated that neonatal DRG neurons
possess a higher molecular weight Nav1.9 that is sensitive to deglycosylation compared to
adults, suggesting that the neonate DRG Nav1.9 is more sialylated than the adult channel.
Voltage-clamp experiments on isolated neonatal and adult DRG neurons indicated that
the Vi for Nav1.9 was hyperpolarized in neonatal neurons compared to adult neurons.
Removal of sialic acids resulted in the Vi for neonatal Nav1.9 being shifted to values
similar to the adult channel Vi, but had no effect on gating of the adult Nav. Nav1.9
displays a great deal of overlap between voltage dependent activation and inactivation
resulting in a relatively large window current[27, 204]. Because of this larger window
current, it is thought that the neonatal Nav1.9 sets the membrane potential and threshold
level for action potential firing in DRG neurons[205, 206]. The authors hypothesized
that the sialic acid-mediated hyperpolarization of SSI in neonatal rat DRG neurons should
increase the window current and thereby increase the persistent Nav activity. In support
of the developmental regulation of VGIC sialylation in the brain, a report by Castillo et
al. in 1998 described a hyperpolarizing change in Va of Nav isolated from rat forebrains
and expressed in lipid bilayers as the animals increased in age[207]. Single channel
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conductance was also altered in channel protein isolated from the adult compared to
protein isolated from the PO and P15 aged rats as described by a significantly shorter f o.
Western blotting indicated that the channel protein was of higher molecular weight as the
developmental stage increased suggesting that glycosylation increased throughout
development of the forebrain. The physiological purpose of altering sialylation levels of
Nav is unknown but, as Tyrell et al. noted, it may cause differential responses to similar
stimuli through development.
In 2006, a study investigating the activities of Nav1.5 in the rat myocardium
showed that all voltage-dependent channel gating parameters measured from isolated
neonatal ventricular myocytes were depolarized compared to Nav1.5 gating parameters
measured from isolated neonatal atrial and adult ventricular and atrial myocytes[178].
The investigators hypothesized that the differences in gating were due to differing levels
of sialic acids found on the channels. Enzymatic removal of sialic acids and of all Nlinked glycosylation using neuraminidase and the enzyme PNGase-F, respectively,
shifted similarly all Nav1.5 voltage-dependent gating parameters measured from neonatal
atrial and adult atrial and ventricular myocytes to values equivalent to those of neonatal
ventricular Nav1.5. Desialylation and deglycosylation had no effect on Nav from neonatal
ventricles. Comparative gel shift analyses suggested that there were approximately 15
more sialic acid residues attached to the neonatal atrial and adult Nav1.5 than were
attached to the less sialylated neonatal ventricular channel. Thus, the data support that a
difference of ~15 sialic acid residues attached to Nav1.5 is fully responsible for the
observed hyperpolarizing shifts in Nav1.5 gating. These data support the idea that VGIC
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glycosylation is variable among cell types, is regulated during development and such
regulated glycosylation modulates VGIC gating.
In an attempt to better understand the role of regulated glycosylation in normal
cardiac physiology and electrical signaling, a study by Montpetit et al. in 2009 observed
that 110 of 239 glycogenes were significantly differentially expressed among neonatal
and adult atrial and ventricular myocytes[177].

Mass spectrometry of atrial and

ventricular protein taken from neonatal and adult mouse hearts showed significant
changes in the types and relative densities of N-glycans, particularly in sialic acid
isotypes as well as in sialyl-linkages, demonstrating a remodeling of the cardiac glycome
among the different myocyte types. This was in agreement with the observed changes in
glycogene profiles. One of the genes demonstrating regulated expression, α-N-acetylneuraminide α-2,8-sialyltransferase 2 (ST8Sia2), is a polysialytransferase found only in
the neonatal atria among the groups tested. To determine if changes in glycogene
expression could lead to functional differences in electrical excitability, the authors
utilized a knock-out (KO) strain homologously deficient in ST8Sia2 (ST8Sia2−/−).
Current-clamp experiments showed significantly longer AP duration (APD) in atrial
myocytes isolated from ST8Sia2−/− neonatal mice compared to wild type controls. There
were no differences in the APD of neonatal ventricular myocytes among the two groups
(ST8Sia2 is not expressed in the neonatal ventricle). In addition to an extension of APD,
the time to AP peak was significantly longer in ST8Sia2-/- neonatal atrial myocytes
compared to controls with no difference in time to AP peak observed in ventricular
myocytes. Alterations in the initiation or upstroke of the AP suggest that Nav function
may be affected. Indeed, whole-cell voltage-clamp experiments demonstrated a ~7mV
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depolarizing shift in G-V and SSI curves, Va and Vi as well as a slowing of fast
inactivation and a more rapid recovery from fast inactivation for atrial ST8Sia2−/− Nav
gating, consistent with other studies investigating the role of sialylation in Nav function
and with the data from the AP recordings. No differences in ventricular Nav gating were
observed between ST8Sia2−/− and control mice. There were also no changes in cell
capacitance or current density among any of the cell types investigated. Immunoblot gel
shift analyses indicated that the level of Nav sialylation is greater in control atria than in
ST8Sia2−/− atria. Additionally, endoneuraminidase (EndoN) treatment, used to remove
polysialic acid chains of five or more residues, indicated that only the control atrial Nav
was polysialylated. These data suggested that ST8sia2 expression and function result in
increased Nav sialylation that modulates Nav gating and contributes to altered AP
waveforms. The results of the study suggested that the regulated expression of only one
of more than 100 glycogenes has functional consequences on cardiac electrical signaling.

1.17. Regulated sialylation modulates excitability through two mechanisms
Thus, there are two proposed mechanisms by which regulated sialylation
modulates excitability: a subunit-specific mechanism (with changes in expression levels
of specific, glycosylated isoforms) and regulated (aberrant) changes in the ability of the
cell to glycosylate VGICs. Both mechanisms may occur simultaneously to produce a
spectrum of possible ion channel gating mechanisms. There is considerable evidence that
suggests differential sialylation has a range of effects on various voltage-dependent
gating mechanisms which would result in a much larger spectrum of possible VGIC
gating motifs.

The consequences of such mechanisms of regulated glycosylation,
40

particularly sialylation, is predicted to result in a greater level of complexity of the
orchestrated and summated activity of these ion channels, leading to altered AP
waveforms, and ultimately to changes in excitability and conduction.

1.18. Differential sialylation likely occurs dynamically and across a spectrum of
rates
The previously described studies together suggest that developmental and cell
specific alterations in sialylation have functional consequences on VGIC gating. From
these data, one might infer that regulated sialylation occurs over a developmental
timeframe or at the rate of protein synthesis. However, there is evidence that both
mechanisms of differential ion channel sialylation may take place on a more dynamic
time scale. For example, internalized surface proteins might reenter directly into the
Golgi glycosylation pathway and be differently sialylated[208]. There is also evidence
that extracellular sialyltransferase and glycosidase expression is regulated and their
activities may rapidly change the level of glycosylation attached to glycoproteins,
resulting in a change in VGIC function[159, 209-213]. In 2007, Isaev et al, reported that
hippocampal network excitability is modulated by endogenous neuraminidase that
removes external sialic acids[214].

If extracellular glycosyltransferase and/or

glycosidase activity is relevant to neuronal function, this might lead to rapid adjustments
to surface channel sialylation.

Thus, the rate of modulation of ion channel gating

imposed through regulated sialylation would occur across a spectrum of rates, ranging
from relatively rapid changes in surface glycan structures to the slower rate of protein
synthesis to the much slower time course of development.
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1.19. The role of aberrant glycosylation/sialylation in cardiac pathology
There are a number of diseases that are caused by aberrant changes in
protein/lipid glycosylation, which in turn, can and often do, lead to reduced sialylation.
Nearly all CDGs are associated with hypotonia and many are associated with more
specific electrical maladies such as arrhythmias and epileptiform activity or seizures[215217]. There are also examples of acquired pathologies that may affect glycosylation,
which then may contribute to the disease symptoms. Chagas disease is caused by a
eukaryotic parasite that produces a trans-sialidase that can remove sialic acids from
mammalian cells[218, 219]. Those afflicted with Chagas disease suffer from arrhythmias
and present with aberrant ECG patterns[220-223]. In other studies, Chronic tachycardia,
resulting in heart failure, induced changes in the glycosylation of the calcium binding
protein calsequestrin[224] and aberrant Nav sialylation was linked to the progression of
cardiac dysfunction in a mouse model of heart failure[202]. The development of type II
diabetes induced by a high fat diet caused changes in the glycosylation state of the
glucose transporter responsible for glucose-stimulated-insulin-release in the pancreas,
which acerbated the condition[225]. Together, many of these examples illustrate how
glycosylation is susceptible to seemingly unrelated disease states possibly through
deviations in normal biochemical pathways or Golgi/ER stress that are often incurred by
such pathologies[226, 227]. It is interesting to note that these examples are also often
associated with electrical remodeling[228, 229], which highlights the idea that changes in
glycosylation, caused by such diseases, may contribute to the pathomechanisms.
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1.20. Developing a model to study the effects of aberrant glycosylation/sialylation on
cardiac excitability
The use of the ST8Sia2-/- strain led to interesting insight into the role of
developmentally regulated sialylation and how it pertains to Nav function and myocyte
electrical signaling in the neonatal atria. In contrast to the expression of ST8Sia2, which
is only expressed in the neonatal mouse atria, the sialyltransferase β-galactoside α-2,3sialyltransferase 4 (ST3Gal4) is uniformly expressed across the developing and adult
myocardium. The enzyme is responsible for adding a sialic acid to galactose residues
through an α-2,3-linkgage that can be linked to core N- or O-linked glycans[153, 177,
230]. ST3Gal4 is 1 of 6 ST3Gals all of which possessing unique specificities involving
both glycoproteins and glycolipids (Fig. 1.9)[153].

Figure 1.9: Function of the sialyltransferase ST3Gal4. A, Schematic diagram
comparing substrate specificities of ST3Gal4 (circled) and five other ST3Gal enzymes.
Figure modified from Varki et al. Essentials of Glycobiology[231] reprinted with
permission. B, ST3Gal4 adds a SA (Neu5Ac) to galactose residues (Gal) through an α23 linkage. Figured modified from Kanehisa et al.[232, 233] reprinted with permission.
http://www.genome.jp/kegg-bin/show_pathway?map00513
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In order to question how aberrant sialylation may affect electrical excitability, which is
consistently observed in diseases of glycosylation, in the adult mouse left ventricle, a
transgenic strain homozygous for a null-ST3Gal4 transgene (ST3Gal4-/-) was used.
Additionally, these studies began to investigate the role of individual glycogene products
and how they relate to Nav and Kv function as well as cardiac electrical signaling. Based
on preliminary data discussed in the introduction describing variable and isoform-specific
effects of reduced sialylation on Nav and Kv gating, channel function was assessed in
cardiomyocytes isolated from the left ventricular apex (LVA) of adult ST3Gal4-/- mice
and compared to WT controls using the whole-cell voltage-clamp recording technique.
The study also explored potential differences in cellular electrical signaling using wholecell current-clamp recordings techniques. Through the use of biochemical techniques,
the following attempted to discern direct changes in sialylation of the various Nav and Kv
isoforms present in mouse ventricular myocytes between the two groups. Finally, based
on potential differences in channel function and cellular excitability, the study
investigated how aberrant sialylation may lead to changes in cardiac and ventricular
conduction through the use of ECG and optical mapping techniques.
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Chapter 2
Materials and Methods

2.1. Generation of the ST3Gal4-/- transgenic strain
ST3Gal4 is 1 of 20 sialytransferases[153, 177]. The ST3Gal4 deficient strain is
healthy, viable and displays no obvious phenotype[234]. Among other functions, the
enzyme is an important mediator in hemostasis, leukocyte arrest and selectin ligand
formation[234-241]. Creation and characterization of the ST3Gal4 deficient mouse was
performed by others previously[234] and generously provided by Dr. Jamey Marth. In
order to genotype the animals used in this study, genomic DNA was extracted from tail
snips using the REDExtract-N-Amp tissue PCR kit (Sigma XNATR) following the
manufactures directions. Genotypes were determined using standard PCR methods with
the following three primers: GAC GCC ATC CAC CTA TGA G, GGC TGC TCC CAT
TCC ACT and GGC TCT TTG TGG GAC CAT CAG.

2.2. Cardiac myocyte isolation
Adult (12-14 weeks old) male mice homozygous for the normal ST3Gal4 gene
(WT) and ST3Gal4-/- mice were anaesthetized using isoflurane (5%) then euthanized by
cervical dislocation. Hearts were rapidly excised from the body and cannulated through
the aorta.

Using a modified Langendorff apparatus, the hearts were perfused and

digested with the following solutions for the indicated times at 36 ± 1°C: 5 minutes with
Hank’s Balanced Salt Solution (HBSS) (Cellgro 21-022) supplemented with 10
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millimoles per liter (mM) of N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid
(HEPES) from a 1 molar stock (Cellgro 25-060), 1 mM MgCl2 from a 1 molar stock
(Ambion AM9530G) and 1 mM CaCl2, pH 7.4; 10 minutes with HBSS supplemented
with 10 mM HEPES and 1 mM MgCl2, pH 7.4; 20 minutes with HBSS supplemented
with 10 mM HEPES, 1 mM MgCl2, 0.1% bovine serum albumin (BSA), 0.025 mM
CaCl2, 20 mM taurine and type 2 collagenase (80 units/ml; Worthington CLS-2), pH 7.4;
and 5 minutes with a high K+ solution containing 100 mM K+ glutamate, 10 mM K+
aspartate, 25 mM KCl, 10 mM KH2PO4, 2 mM MgSO4, 20 mM taurine, 5 mM creatine
base, 0.5 mM ethylene glycol tetra acetic acid (EGTA), 5 mM HEPES, 0.1% BSA, and
20 mM glucose, pH 7.2 as described by others[242]. At the completion of the perfusion
scheme described above, the bottom 2 millimeters of the LVA was cut and dispersed in
the high K+ solution for approximately 10 minutes to obtain individual myocytes. The
suspension was filtered and cells were allowed to sediment by gravity. Myocytes were
maintained at room temperature in the high K+ solution until use 1-4 hours following
isolation.

2.3. Electrophysiology
0.2-0.5 ml of the myocyte suspension were added to a recording chamber (Warner
RC-26) mounted on a Nikon TE200 microscope. Cells were allowed to settle for 5
minutes on laminin (BD 354232) coated cover slips.

Once the cells adhered,

approximately 5 volumes of extracellular recording solution (ECS) were perfused
through the chamber. Patch pipettes were fabricated using a horizontal pipette puller
(Sutter P97), filled with an intracellular recording solution (ICS) and mounted on a
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headstage (Axon Instruments CV203BU).

Immediately prior to seal formation, the

solid/liquid junction offset was zeroed manually using the pipette offset on an Axopatch
200B amplifier with β set to 0.1. Following seal formation of at least one gigaohm, the
whole cell-configuration of the patch clamp method was obtained[243]. Analog signals
recorded by the amplifier were low-pass filtered at 5 kilohertz (kHz) then digitized at a
rate of 50 kHz using a Digidata 1440A analog/digital interface connected to a personal
computer. For recording INa in voltage-clamp mode, cell size was determined by
integrating the capacitance of the cell following a 25 ms 10 mV step in voltage from a
holding potential of -100 mV. After measuring cell size, resistances and capacitances
were minimized manually using the amplifier and oscilloscope found in the Axon
Clampex 10.2 software. Patch Pipettes (Warner G150F-3) had a mean series resistance
of approximately 1.4 ± 0.1 (n=24) megaohms (MΩ) when filled with an ICS (Table 1).
All solutions were filtered (0.22 microns) and either stored at -20˚ C (ICS) or 4˚ C (ECS)
Series resistances were compensated for as necessary but to a minimum of 80%. The
currents were leak subtracted using the P/5 method from the holding potential of -100
mV and in the opposite polarity as the current waveforms. The maximum mean voltage
errors from uncompensated series resistances were approximately -6.5 ± 0.6 and -6.0 ±
0.7 mV when recording from control (n=11) and ST3Gal4-/- (n=13) LVA myocytes
respectively and were ignored. The ECS used to record INa is found in table 1; an
ICS/ECS junction potential of -0.5 mV was calculated using the junction potential
calculator in Clampex and was also ignored.
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Table 2.1: Electrophysiological recording solutions

CsCl
CsF
EGTA
HEPES
MgATP
Glucose
NaCl
CaCl2
MgCl2
CdCl2
KAsp
KCl
Na2HP04
K2ATP
TTX

INa
ICS
7.2
CsOH

INa
ECS
7.35
CsOH

25.0
110.0
10.0
10.0
5.0
5.0
5.0
---------

130.0
--10.0
-10.0
11.0
0.5
1.0
0.3
------

Cell
Cell
IK
Refract Refract ICS
ICS
ECS
7.2
7.2
7.4
KOH
NaOH
NaOH
Millimoles/Liter
--------10.0
10.0
10.0
10.0
5.0
-1.0
5.0
10.0
5.0
8.0
130.0
--1.0
--1.0
----110.0
--20.0
5.4
135
-0.33
---4.1
----

IK
ECS
7.4
NaOH

AP
ICS
7.2
KOH

AP
ECS
7.4
NaOH

---10.0
-10.0
136.0
0.5
1.0
0.25
-5.4
--0.02

--10.0
10.0
1.0
5.0
-----135
-4.1
--

---10.0
-10.0
130.0
1.0
1.0
--5.4
0.33
---

Table 1 Legend: INa, voltage-gated sodium current; ICS, intracellular recording solution;
CsOH, cesium hydroxide; ECS, extracellular recoding solution; Cell Refract, cellular
refractory period; NaOH, sodium hydroxide; IK,voltage-gated potassium current; KOH,
potassium hydroxide; AP, action potential; CsCl, cesium chloride; CsF, cesium fluoride;
HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid; MgATP, magnesium
triphosphate; NaCl, sodium chloride; CaCl2, calcium chloride; MgCl2, magnesium
chloride; CdCl2, cadmium chloride; KAsp, potassium aspartate; KCl, potassium chloride;
Na2HPO4, sodium phosphate dibasic; K2ATP, potassium triphosphate; TTX, tetrodotoxin.
For recording cellular refractory period in current-clamp mode, patch pipettes (Chase
502) had a mean series resistance of approximately 2.5 ± 0.03 (n=26) MΩ from a holding
potential of -70 mV when filled with an ICS (Table 1). The cellular refractory period
ECS is found in table 1 and the ICS/ECS junction potential was calculated to be
approximately -21 mV and was added off-line. When recoding IK in voltage-clamp
mode, cell capacitances were calculated as described above but from a holding potential
of -70 mV. Patch pipettes (Chase 502) had a mean series resistance of 2.9 ± 0.2 MΩ
(n=20). Leak currents were always less than 80 pA and were ignored. The ICS/ECS
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(Table 1) junction potential was 4.4 mV and was also ignored. Series resistances and
capacitances were minimized as described above and were compensated to a minimum
value of 80%. The maximum voltage errors from uncompensated series resistances were
-8.0 ± 1.0 and 7.4 ± 1.3 mV for WT and ST3Gal4-/- respectively (n=10) and were
ignored.

To record APs in current-clamp mode, patch pipettes had a mean series

resistance of 2.6 ± 0.3 MΩ (n=18) from a holding potential of -70 mV. The ICS/ECS
(Table 1) was calculated to have a junction potential of -4.8 mV and was added offline.
Voltage and current clamp protocols were written and executed using Clampex 10.2 and
the ICS was allowed to dialyze for 5 minutes following cell rupture.

2.4. Voltage clamp protocols: INa

Current density and conductance-voltage relationships: INa
Cells were held at -100 mV then depolarized by a series of voltage steps
beginning at -85 mV and ending at 30 mV for 120 ms in 5 mV increments. Each voltage
step was separated by 1.5 seconds and the current was leak subtracted using the P/5
method from the holding potential and in the opposite polarity as the current waveform.
The current elicited from each test pulse was divided by the cell capacitance to report
current density as A/F or the current was divided by the driving force using the following
equation to determine Na+ conductance (G):
G = INa / (Vpot -Vrev)
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where INa is the sodium current at each test potential, Vpot is the test potential and Vrev is
the Nernst equation-derived reversal potential at 22° C (20.05 mV).

Conductance-

voltage relationships were fit with a Boltzmann equation of the form:
Fraction of Maximum Conductance (G/Gmax) = [1+ (e –((Vpot -Va)/Ka))] -1
where Gmax is the maximum theoretical conductance, Va is the voltage of half-activation
and Ka is the slope of the Boltzmann fit for activation as previously described[178]. The
Gmax, Va, and Ka for each cell were determined by fitting the single cell data to a single
Boltzmann distribution, and were used to determine the mean parameter values among
cells as listed in Table 1. Also, the Gmax was used to normalize cellular data.

Voltage-dependent inactivation: INa
Cells were held at -100 mV and subjected to conditioning voltage pulses ranging
from -140 mV to -65 mV in 5 mV increments for 500 ms. Following the conditioning
pulses, the cells were depolarized to -20 mV for 10 ms. Currents were normalized to the
maximum current and the data were fit with the following Boltzmann equation:
Fraction of Maximum Current (I/Imax) = [1+ (e –((Vpot-Vi)/Ki))] -1
where I/Imax is the ratio of each current to the maximum current, Vpot is the potential of
each conditioning pulse, Vi is the voltage of half-inactivation and Ki is the slope of the
Boltzmann fit for inactivation as previously described[178]. The Imax, Vi, and Ki for each
cell were determined by fitting the single cell data to a single Boltzmann distribution, and
were used to determine the mean parameter values among cells as listed in Table 3.
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Time constants of fast inactivation (inact): INa
The attenuating portion of the current traces recorded during the current
density/conductance-voltage measurements were fit with a single exponential function
with the form:
f(t) = Ae-t/tau + C
where A is the amplitude in picoamps (pA), t is the time in ms, tau is the time in ms it
takes for the current to inactivate one exponential unit and C is a constant.

Time constants for recovery from fast inactivation (rec): INa
Two distinct recovery protocols were performed and in both cases, cells were held
at a voltage of -100 mV then depolarized to -20 mV for 50 ms. In one of the protocols
the membrane potential was returned to -100 mV for a duration of initially 1 then a delta
of 5 ms followed by a second depolarization to -20 mV for 50 ms. In the second
protocol, following the initial pulse to -20 mV, the membrane potential was changed to 90 mV for a duration of initially 10 then at a delta of 10 ms followed by a second pulse to
-20 mV for 50 ms. Between each pulse the membrane potential was returned to -100 mV
for 4 seconds. The current elicited from the second pulse to -20 mV was normalized to
the current from the initial pulse to -20 mV for each sweep. The data was fit with a
single term exponential with the form:
I2/I1 = A(1-e-t/tau) + C
where I2/I1 is the ratio of the current elicited from the second -20 mV pulse to the current
elicited from the initial -20 mV pulse, A is the asymptote of the curve, t is the time in ms,
tau is the time it takes the curve to rise one exponential unit and C is a constant. In some
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cases, curve fitting was marginally improved when a bi-exponential function was used.
However, in many cases such a fit provided nonsensical results; therefore, a single
exponential was used in these studies.

2.5. Cellular refractory period
Following cell rupture, the membrane potential was measured.

Cells were

injected with positive current for a duration of 4 ms with an initial current step of 100 pA
followed by subsequent current steps with a delta of 50 pA. Each sweep was separated
by 2 s. Threshold was determined by the first overshooting AP that preceded at least two
more similar action potentials.

The threshold current was calculated and a current

amount of 125% of threshold was used in a two pulse protocol to estimate the cellular
refractory period. Cells were stimulated with a current pulse of 125% of threshold for 4
ms followed by a second pulse 5 ms later and then each additional pulse came with a
delta of 8 ms. The pulse number that elicited an overshooting AP that preceded at least 2
more similar APs was used to estimate the refractory period.

2.6. Voltage clamp protocols: IK

Current density and conductance-voltage relationships: IK
Cells were held at -70 mV then depolarized by a series of voltage steps beginning
at -50 mV and ending at 50 mV for 4.5 seconds in 10 mV increments. Each voltage step
was separated by 10 seconds. The decaying portion of each current trace was fit with the
following bi-exponential function:
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f(t) = IKslow e-t/tau1 + Ito e-t/tau2 + ISS
where IKslow is the amplitude of the slowly inactivating portion of each current trace, t is
the time in ms, tau1 is the time it takes IKslow to inactivate one exponential unit, Ito is the
amplitude of the rapidly inactivating portion of each current trace, tau2 is the time in ms
it takes Ito to inactivate one exponential unit and ISS is the amplitude of the noninactivating portion of each current trace. This method, as a means to delineate the
different IK in the mouse ventricle, was described by others previously[31].

The

amplitudes of each kinetic component, derived from the above equation, for each current
trace were divided by the cell capacitance to report current density as A/F or the current
was divided by the driving force using the following equation to determine conductance
(G):
G = I / (Vpot -Vrev)
where I is the current at each test potential, Vpot is the test potential and Vrev is the Nernst
equation-derived reversal potential at 22°C (83.4 mV).

Conductance-voltage

relationships were fit with a Boltzmann equation of the form:
Fraction of Maximum Conductance (G/Gmax) = [1+ (e –((Vpot -Va)/Ka))] -1
where Gmax is the maximum theoretical conductance, Va is the voltage of half-activation
and Ka is the slope of the Boltzmann fit for activation as previously described[178]. The
Gmax, Va, and Ka for each cell and current type (kinetic component) were determined by
fitting the single cell data to a single Boltzmann distribution, and were used to determine
the mean parameter values among cells as listed in Table 4. Also, the Gmax was used to
normalize cellular data.
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Voltage-dependent inactivation: IK
Cells were held at -70 mV and subjected to conditioning voltage pulses ranging
from -110 mV to 0 mV in 10 mV increments for 10 seconds. Following the conditioning
pulses, the cells were depolarized to 30 mV for 4.5 seconds. Each sweep was separated
by 10 seconds. Decaying portion of each current trace elicited from each voltage step to
30 mV was fit with a bi-exponential function as described above.

The maximum

amplitudes of each current type (kinetic components) from each current trace were
normalized to their corresponding maximum values from the first step to 30 mV. The
data were fit with either a single Boltzmann equation for Ito or a double Boltzmann
equation for IKslow:
Fraction of Maximum Current Ito (I/Imax) = [1+ (e –((Vpot-Vi)/Ki))] -1
Fraction of Maximum Current IKslow (I/Imax) =
[(1+ (e –((Vpot-Vi1)/Ki1))) +(1+ (e –((Vpot-Vi2)/Ki2)))] -1
where I/Imax is the ratio of each current to the maximum current, Vpot is the potential of
each conditioning pulse, Vi1 and Vi2 are the voltages of half-inactivation and Ki1 and Ki2
are the slopes of the Boltzmann fit for inactivation as previously described[178]. The
Imax, Vi, and Ki for each cell and for each current type were determined by fitting the
single cell data to a single Boltzmann distribution, and were used to determine the mean
parameter values among cells as listed in Table 4.

Time constants of inactivation (inact): IK
The time constants of inactivation were recorded from the bi-exponential fit as
described above used to calculated current densities and G-V values. IKslow is represented
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by tau1 and Ito is represented by tau2. Where tau is the time in ms it takes for the current
to inactivate one exponential unit.

2.7. Action potential recordings
Following cell rupture, the membrane potential was measured.

Cells were

injected with positive current for a duration of 4 ms with an initial current step of 100 pA
followed by subsequent current steps with a delta of 50 pA. Each sweep was separated
by 2 s. Threshold was determined by the first overshooting AP that preceded at least two
more similar action potentials.

The threshold current was calculated and a current

amount of 125% of threshold was used to measure AP parameters (Table 5). The mean
values from five replicate current pulses of 125% of threshold delivered for a duration of
4 ms at 0.25 Hz were calculated.

2.8. Optical mapping
Left ventricular epicardial conduction was studied using optical mapping methods
similar to that previously described[244-246]. Following anesthesia with isoflurane (5%)
adult ST3Gal4-/- and WT mice were euthanized by cervical dislocation. Hearts were
rapidly excised, cannulated through the aorta and perfused with a Kreb’s solution at
37°C. Following equilibration, healthy hearts were stained with a voltage sensitive
fluorescent dye, RH237 (Biotium). A green light (20-Watt green LED passing through
an additional 520 ± 25 nm filter) excited the dye. An optical mapping system with two
CMOS monochrome data cameras (Ultima, Scimedia) collected the fluorescence from a
6x6 mm2 area on the epicardial surface of the left ventricle, converted it to electrical
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signals and then recorded movies of APs (690 nm long-pass filtered) at 500 frames/sec. A
bipolar electrode was placed on the left ventricular epicardium to deliver stimulating 2
ms pulses. The stimulation threshold was determined first by repetitively stimulating the
heart with progressively decreasing current until cardiac activation was no longer
observed. Subsequent stimulations used 2x the activation threshold. To determine the
minimum refractory period, the heart was stimulated repetitively with progressively
decreasing S1-S2 pacing intervals until the S2 stimulus failed to stimulate a response.
Conduction velocity was measured (using BV-ANA software, Scimedia) along a line
starting at or near the site of stimulation and perpendicular to the smoothest conduction
wavefronts.

To determine susceptibility to arrhythmias, the heart was stimulated

repetitively using trains of 2-6 pulses at intervals 5 ms longer than the measured
refractory period. Recorded data were analyzed using visual identification to characterize
pacing induced arrhythmias, including, ventricular tachycardia (V.Tach., at least a
doubling of the rate), reentry (observed as an anomalous conduction loop),
afterdepolarization (observed as an aberrant excitation event), and/or ventricular
fibrillation (V. Fib.). Optical mapping data was collected by Kofi-Kermit Horton and
Jiashin Wu and analyzed by Jiashin Wu.

2.9. Electrocardiograms
Adult (12-14 week) mice were anesthetized with isoflurane (5%) and transmitters
(DSI TA10ETA-F20) were implanted into the abdominal cavity. The leads were sutured
to muscles in upper right section of the thorax and near the apex of the heart. The
animals were allowed to recover for one week following the surgery.

ECGs were
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recorded from conscious unrestrained mice continuously over 48 hour periods using
telemetry via a data exchange matrix (PhysioTel Receivers RPC-1). Recorded data was
analyzed using Data Quest ART and Ponemah (DSI PNM-P3P-ECG) software. Analysis
of the ECGs included comparison of the specific characteristics such as RR interval
(heart rate), PR segment, QT segment (when possible) and P wave characteristics.
Analysis will also include observations of the ECG waveforms to investigate for aberrant
conduction events that will include premature ventricular contractions, heart rate
variability and anomalous conduction/arrhythmias. For studies involving isoproterenol, a
stock solution was made by dissolving the appropriate amount of isoproterenol into
normal saline followed by filtration (0.22 microns). Working solutions were then made
by diluted with normal saline and dosages were delivered intraperitoneally.

2.10. Membrane protein enrichment
Adult male WT and ST3Gal4-/- mice between the ages of 12 and 14 weeks were
anaesthetized using isoflurane then euthanized by cervical dislocation. The lower 2/3 of
the heart consisting of both the right and left ventricles was separated and then snap
frozen in liquid nitrogen. The following protocol, which was previously described by
others[247], and solutions were all performed and maintained at 4° C. Two hearts per
group were homogenized using glass douncers and sonication in 3 ml of extraction
solution consisting of 20 mM trishydroxymethylaminomethane (Tris)-base, 5 mM
Ethylene diamine tetra acetic acid (EDTA), 0.8 mM benzamidine, 1 mM iodacetamide,
1.1

μM

leupeptin,

0.7

μM

pepstatin,

76.8

nM

aprotinin

and

0.5

mM

phenylmethanesulfonylfluoride; pH 7.5. The suspension was centrifuged at 1000xG for
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ten minutes and the supernatant was aspirated. The pellet was re-homogenized in 2.5 ml
of extraction solution and centrifuged at 1000xG for ten minutes. Both supernatants were
pooled and centrifuged at 40,000xG for ten minutes. The resultant pellet was suspended
in extraction solution supplemented with 0.6 molar KCl for ten minutes to dissociate the
cytoskeleton. The suspension was centrifuged at 40,000xG for ten minutes and the pellet
was suspended in extraction solution; this was repeated twice to ensure the removal of
KCl. The final pellet was solubilized in extraction solution supplemented with 2% Triton
X-100 for 1 hour with periodic sonication. The suspension was centrifuged at 10,000xG
for 10 minutes and the supernatant was aspirated.

Protein concentrations were

determined using a BCA assay (Pierce 23237) and the protein solutions were stored at 80° C until use.

2.11. Western blotting and immunodetection
Western blotting for densitometry analysis was performed using protocols
adapted from Invitrogen’s Novex system. Membrane enriched protein was mixed 1:1 in
a sample buffer that contained 106 mM Tris HCl, 141 mM Tris-base, 2% lithium dodecyl
sulfate (LDS), 10% Glycerol, 0.51 mM EDTA, 0.075% Coomassie Blue R250 and
0.025% phenol red, pH 8.5.

Nav are large proteins with 24 hydrophobic-rich

transmembrane segments that can aggregate when exposed to high temperatures;
therefore, protein was denatured at 37°C. Protein used for Kv immunodetection was
denatured at 70°C for 10 minutes. 20µg (Nav) or 40μg (Kv) of protein was loaded into
the wells of a 4% Bis-Tris stacking gel.

Protein was separated electrophoretically

through an 8% Bis-Tris resolving gel using a 3-N-morpholinopropanesulfonic acid
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(MOPS)-SDS buffer, pH 7.7 supplemented with 5mM sodium bisulfite at 200 V.
Following electrophoresis, proteins were transferred to nitrocellulose membranes (Nav)
(GE Healthcare RPN3032D) or polyvinylidene fluoride (Kv) (PVDF: Millipore
IPVH00010) using a tank transfer system (Bio-Rad 170-3930) at 4° C for 2 hour at 50 V.
The transfer solution consisted of Bis-Tris 25mM, bicine 25mM, EDTA 1mM, sodium
bisulfite 5 mM, 20% methanol and 0.0375% SDS. Blots were rinsed briefly then dried at
room temperature and either used immediately or stored at 4°C.
Following western blotting, Nav and Kv visualization was performed using
Millipore’s SNAP ID system following the manufacturer’s recommendations.
Membranes were blocked with 0.5% non-fat dairy milk. A pan-Nav antibody, which was
described previously[178, 248], was used as the primary antibody and a goat anti-rabbit
horseradish- peroxidase (HRP) conjugated antibody (Millipore AP307P) was used as the
secondary. The following table describes the commercially available antibodies used to
detect the various Kv isoforms.
Table 2.2: Antibodies used for Kv detection
Kv Isoform Manufacturer Part Number
Kv4.2

Upstate

07-491

Kv1.5

Alomone

APC-004

Kv2.1

Neuromab

75-014

Nav and

Kv

protein

levels

were

Secondary
Goat anti-rabbit HRP (Millipore
AP307P)
Goat anti-rabbit HRP (Millipore
AP307P)
Goat anti-mouse HRP (Millipore
AP308P)

normalized

to

Glyceraldehyde-3-phosphate

dehydrogenase (GAPDH) protein expression using a mouse monoclonal antibody raised
against GAPDH (Santa Cruz SC32233) as the primary and a HRP conjugated goat antimouse antibody as the secondary (Millipore AP308P). Blots were incubated with a
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chemiluminescent substrate following the manufacturer's recommendations (Pierce
34080). A Tris buffered solution (TBST) consisting of 50 mM Tris, 0.154 mM NaCl and
0.1% tween, pH 7.5 was used as the diluent and wash solution for the immunodetection
protocol.

Following the chemiluminescent reaction, bands were visualized with

autoradiography film (Midsci BX57), scanned and densitometry was performed using the
National Institute of Health's ImageJ software application.

2.12. Gel-shift analysis
Sarcolemmal

protein

was

enriched

and

isolated as

described

above.

Approximately 25 µg of protein was diluted to 10 µl with 20 mM Tris-base (pH 7.5)
along with 0.5% LDS, 2X HALT protease inhibitor cocktail (Pierce 87785) and either 1
U/ml of sialidase A (Prozyme GK80040) or a equal volume of 20 mM Tris-base/25 mM
NaCl. The solution was incubated for 2 hours at 37° C. Following incubation, the
solution was mixed 1:1 with a Lammeli-style sample buffer consisting of 62.5 mM Trisbase pH 6.8, 25% glycerol, 2% LDS, 0.01% bromomethyl blue and 5% βmercaptoethanol and denatured at 37°C.

Denatured protein was added to a 4.5%

Tris/glycine gel and separated electrophoretically as previously described[178]. Gels
where then blotted onto nitrocellulose membranes using a semi-dry transfer apparatus
(Bio-Rad 170-3940) at 15 V for 26 minutes in a transfer buffer consisting of Tris-base 48
mM, glycine 39 mM, 20% methanol and 0.0375% SDS. Following transfer, blots were
rinsed briefly and allowed to air dry at room temperature. To determine differences in
apparent molecular weight (MW), scanned film was analyzed using ImageJ. The log of
each MW marker was plotted versus its distance in arbitrary units traveled into the gel. A
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linear regression was then performed and used to calculate the MW of sialidase-treated
and untreated protein.

2.13. Statistical analyses
Data was analyzed with excel, clampfit and Sigmaplot 11.0 where appropriate.
Reported values are the mean ± SEM. Student’s t-test and one-way ANOVA with the
Holms-Sidak method was used to determine statistical significance were appropriate.
Mann-Whitney rank sum test was used when values were not normally distributed

p

values are reported as calculated but were considered significant when less than 0.05.
For electrophysiological measurements, sample numbers (n) are reported as the number
of cells. For all groups, cells originated from 4-6 different animals.
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Chapter 3
Results

3.1. Introduction
The sequential glycosylation process typically ends with negatively charged sialic
acid

residues

added

through

trans-Golgi

sialyltransferase

activity[153,

157].

Sialytransferases are a group of 20 enzymes with unique substrate specificities, which
include both glycoproteins and glycolipids[153]. Sialyltransferases belong to a much
larger group of glycogene products that number in the hundreds responsible for creating a
complex and variable glycan profile (glycome) unique to different cell types and
tissues[177]. Sialic acid impacts Nav and Kv function and developmentally regulated
sialylation contributes to cardiac myocyte excitability in the neonatal mouse atria[249,
250].

However, little is understood concerning how the glycosylation machinery

(glycogene products) influences cell and tissue electrical signaling. The sialytransferase
β-galactoside α-2,3-sialyltransferase 4 (ST3Gal4) adds sialic acids to galactose residues
through an α-2,3-linkgage to core N- or O-linked glycans[153, 177, 230]. ST3Gal4 is
uniformly expressed throughout the chambers and developmental stages of the heart and
therefore is likely a useful target to question whether and how glycosylation impacts
these events[177]. Additionally, diseases of glycosylation often cause symptoms that are
consistent with changes in excitability that include arrhythmias and seizures[165, 215,
216, 251, 252].

Diseases that affect glycosylation, such as CDG, do so variably

throughout the glycosylation process; however, sialic acids are typically the terminal
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residues of glycan structures therefore truncated glycans, as a result of pathological
glycosylation, will often result in fewer sialic acids added. In addition, Chagas disease,
which results in pathological changes to cardiac electrical signaling, may reduce sialic
acids directly[218-223, 253]. Because of this, the ST3Gal4-/- strain was also used to
investigate the role of glycosylation in the pathological cardiac electrical remodeling
often associated with these diseases. The methodologies included cellular, tissue and
whole-animal electrophysiology as well as biochemical assays. The data indicate that
deletion of a single sialyltransferase, ST3Gal4, significantly affects Nav sialylation and
gating with no change in maximum current density or protein expression. ST3Gal4
deletion also depolarizes the activation gating of both voltage-dependent kinetic
components of repolarization found in the mouse ventricle: Ito and IKslow; however unlike
the effect on INa, ST3Gal4 gene deletion causes a reduction in the peak IK density.
Protein expression of the putative Kv isoforms responsible for Ito and IKslow was variably
affected by ST3Gal4 gene deletion with Kv1.5 and Kv4.2 demonstrating no differences in
protein densities. Contrastingly, a small but significant reduction in Kv2.1 protein from
ST3Gal4-/- ventricular tissue was observed. ST3Gal4 expression is necessary for normal
cellular electrical signaling as demonstrated by a reduction in cellular refractory period
and alterations in AP waveforms that include a slowing of cellular conduction and an
extension of AP duration in ventricular myocytes from ST3Gal4-/- mice. Concurrent with
aberrant excitability at the cellular level, the ST3Gal4-/- left ventricular epicardium
demonstrated a reduced refractory period and was more susceptible to arrhythmias as
observed through optical mapping studies. Additionally, ECGs of ambulatory ST3Gal4-/mice demonstrated that deletion of the gene causes modest aberrant conduction under
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basal conditions and, in preliminary studies, appears to increase the susceptibility to
arrhythmogenesis following a cardiac challenge, in the form of a low dosage of the βadrenergic agonist isoproterenol, suggesting a reduction in repolarization reserve in the
ST3Gal4 heart. Based on the data reported here, it is apparent that relatively minor
perturbations in the cardiac glycome cause significant changes in cardiac electrical
signaling. These data highlight the role of glycosylation in normal physiology and
underscore it as an important mediator in diseases where it may be altered.

3.2. Deletion of ST3Gal4 alters Nav gating but has no effect on maximum current
density
To determine the effect of gene deletion of the sialyltransferase ST3Gal4 on
cardiac INa, the whole-cell patch-clamp recoding technique was performed on adult LVA
myocytes isolated from WT and ST3Gal4-/- mice. At relatively small depolarizations,
current densities were smaller in ST3Gal4-/- myocytes compared to WT myocytes with no
effect observed at greater depolarizations (Fig. 3.1B), suggesting that Nav gate differently
with ST3Gal4 expression. Mean cell capacitances for the two groups were similar (Table
3.1). G-V relationships were measured to determine the voltage-dependence of steadystate activation (Fig. 3.2A).

The INa G-V relationships recorded from ST3Gal4-/-

myocytes were more depolarized than those from WT myocytes. Boltzmann fits of the
data showed a significant depolarizing shift of ~4 mV in Va for ST3Gal4-/- Nav compared
to WT controls with no difference in maximum conductance density between groups
(Fig. 3.2B, Table 3.1).
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Figure 3.1: ST3Gal4-/- ventricular INa density is reduced at smaller depolarizations
compared to WT controls but similar at more depolarized potentials. Here and
throughout unless noted, WT (Black circles/lines/bars; n=11) and ST3Gal4-/- (Red
diamonds/lines/bars; n=13). Data are mean ± SEM. A, Pulse protocol and representative
whole myocyte INa traces. Detailed pulse protocols are listed in the methods. B, Current
density-voltage relationships. *p≤0.032.
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Similarly, depolarizing shifts of ~4 mV in Vi (Fig. 3.3) and in SSI (Table 3.1) were also
observed in ST3Gal4-/- myocytes compared to WT controls, indicating that both voltagedependent events required a greater depolarization to occur and were similarly affected
by ST3Gal4 gene deletion. There were no differences in the slopes of the Boltzmann fits
for G-V or SSI curves (Table 3.1), indicating that ST3Gal4 expression does not modulate
the magnitude of charge translocation and/or stability of intermediate states during
voltage-dependent Nav gating. In additional studies, isolated LVA myocytes from WT
mice were treated with sialidase A (50 mU/ml, 2-3 hours, 22 ± 1°C) to remove surface
sialic acid residues. Similar depolarizing shifts of ~4 mV in Va (n=10; p<0.001) and 3
mV in Vi (n=10; p=0.031) were observed verifying that the changes in ST3Gal4-/- Nav
gating were consistent with a reduction in Nav sialylation.
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Figure 3.2: ST3Gal4-/- Nav activation gating is shifted to more depolarized potentials
with no change in maximum conductance density. A, Steady-state activation curves
(conductance-voltage, GV relationships). *p≤0.001. Lines are best fits of the data to
single Boltzmann function. B, Bar graphs of maximal conductance density. Maximal
conductance for each cell was determined by best fits of G-V data for each cell.
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single Boltzmann functions. Insets: Steady-state inactivation pulse protocol and
representative current traces.
To test whether the observed rightward shift in Va corresponded with a slowing of
fast inactivation, the decaying portion of each current trace was fit with a single
exponential function. At relatively small depolarizations, the time constants of fast
inactivation (inact) were significantly longer in ST3Gal4-/- myocytes compared to WT
myocytes (Fig. 3.4, Table 3.1). At further depolarizations, no statistically significant
differences in inact were apparent indicating that the impact of ST3Gal4 expression on
fast inactivation was likely mediated through a voltage-dependent process.
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Next, the rate of recovery from fast inactivation was determined using a standard
twin pulse protocol. At recovery potentials of -90 mV (Fig. 3.5A) and -100 mV (Fig.
3.5B), the time constants for recovery from fast inactivation (rec) decreased by ~23% in
the ST3Gal4-/- myocytes compared to WT myocytes (Fig.3.5C, Table 3.1). Attempts to
measure the rate of recovery from inactivation at the normal resting membrane potential
demonstrated little to no recovery in Nav. This is likely due to the to the lower Na+
concentration in the ECS, which was used to maintain adequate voltage and space clamp
integrity. However, previous studies have suggested that the effect of sialic acid on
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recovery from fast inactivation is voltage-dependent and as the test potential becomes
more depolarized the effect on recovery is increased[176, 178]. Based on this, it is likely
that at the measured membrane potential of ~-79 mV (as described in a subsequent
section), the effect on recovery should be of even larger magnitude.
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Table 3.1: The mean ± SEM INa gating parameter values.

Group
WT
(n=11)
ST3Gal4-/(n=13)

Cm
pF

GMax/Cm
(S/F)

Va
(mV)

177.3±15.5

1.1±0.1

-52.4±0.6

161.4± 9.3

1.1±0.1

-48.5±0.6*

Ka
(mV)

Vi
(mV)

Ki
(mV)

inact(-60)
(ms)

inact(-55)
(ms)

inact(-50)
(ms)

rec(-100)
(ms)

rec(-90)
(ms)

5.6±0.3

-90.8±1.1

-6.5±0.3

9.0±0.6

4.7±0.3

3.1±0.1

24.0±0.9

69.7±1.4

6.0±0.3

-87.2±0.7*

-6.1±0.3

13.5±0.9*

7.3±0.6*

3.9±0.3*

18.6±1.2*

53.9±2.2*

Cm, cell capacitance. Gmax, maximum conductance. Significance was determined using a two-tailed Student's t test comparing WT
and ST3Gal4-/- groups. * p≤0.015.
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3.3. Nav protein levels are unaltered but ST3Gal4-/- ventricular Nav are less sialylated
Western blot analysis of sarcolemmal-enriched protein was used to determine
potential differences in Nav expression patterns between WT and ST3Gal4-/- ventricular
tissue. Figure 3.6A depicts a representative blot probed with a pan-Nav polyclonal
antibody. Optical density of Nav bands in arbitrary units (AU) were determined and
compared to GAPDH AU (8 samples/4 hearts per group), with no difference in Na v
protein expression between ST3Gal4-/- and WT ventricular tissue detected (Fig. 3.6B).
Additionally no difference in GAPDH expression was observed (data not shown). These
data, along with the current density and maximum conductance data (Figs. 3.1B and
3.2B), indicate that expression of ST3Gal4 does not confer any significant change in Nav
surface expression or stability. In the majority of blots, it was apparent that Nav protein
isolated from WT ventricular tissue was of higher apparent molecular weight (MW) than
ST3Gal4-/- Nav protein. As previously reported, a decrease in MW of ST3Gal4-/- Nav
protein is consistent with less sialylated Nav[177, 178]. To test this, protein from both
groups was treated with sialidase A (Fig. 3.7). Compared to WT Nav, untreated Nav
protein from ST3Gal4-/- ventricular tissue migrated farther, consistent with a 5.5 ± 1.6 kD
shift (Fig. 3.7; n=7; *p<0.001). Following sialidase treatment, the measured MW from
both groups was reduced to nearly identical levels.

However, compared to their

respective untreated proteins, sialidase-treated WT protein shifted approximately 10.1 ±
0.7 kD while sialidase-treated ST3Gal4-/- protein shifted approximately 5.3 ± 1.2 kD.
These data suggest that Nav from ST3Gal4-/- ventricular tissue are sialylated but likely
have fewer sialic acid residues attached than WT channels.
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Figure 3.6: Nav protein expression is similar in ST3Gal4-/- ventricular tissue
compared to WT control. A, Representative western blot of sarcolemmal enriched Nav
protein (left panel) and GAPDH (right panel) taken from WT and ST3Gal4-/- ventricular
tissue. B, Bar graph demonstrating no difference in Nav protein expression in ST3Gal4-/compared to WT ventricles.
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Figure 3.7: ST3Gal4-/- Nav protein is of lower apparent molecular weight and is less
sensitive to desialylation than WT. Gel-shift analysis: Sarcolemmal enriched protein
was treated with sialidase A. Data suggest that ST3Gal4-/- Nav protein (solid black line)
is of lower MW than WT Nav protein (solid red line). The measured MW from WT and
ST3Gal4-/- protein were nearly identical following enzymatic desialylation, but WT
protein (dashed black line) demonstrates a greater MW shift than ST3Gal4-/- protein
(dashed red line). The mean ± SEM MW shifts for each sample compared to untreated
WT protein is listed at the bottom of the blot (n=7; *p<0.001).
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3.4. Cellular refractory period is shorter in ST3Gal4-/- LVA myocytes
Nav recovery from fast inactivation plays a pivotal role in refractory period and in
cardiac conduction.

To test whether the observed differences in Nav recovery in

ST3Gal4-/- myocytes lead to differences in cellular refractory period, current-clamp
experiments were performed on LVA myocytes isolated from ST3Gal4-/- and WT mice
(Fig. 3.8). EGTA was omitted from the ICS in order to better simulate normal myocyte
electrical signaling where Ca2+ would contribute. There were no significant differences
between the mean ST3Gal4-/- and WT control resting membrane potentials (ST3Gal4-/- =
-79.7 ± 0.8 mV; WT = -79.9 ± 1.1 mV, p=0.9) or the threshold of AP firing (ST3Gal4-/- =
538.7 ± 43.9 picoamps; WT = 524.5 ±50.8 picoamps, p=0.8). However, concurrent with
an acceleration in Nav recovery from fast inactivation, the cellular refractory period was
significantly shorter in ST3Gal4-/- LVA myocytes by approximately 30 ms (139.8 ± 8.6
ms for WT n=13 and 110.2 ± 10.0 ms for ST3Gal4-/- n=13; p=0.035; (Fig. 3.8A and B).

3.5. ST3Gal4 gene deletion affects repolarizing K+ currents
Repolarization in adult mouse ventricular myocytes occurs primarily through the
action of three kinetically distinct K+ current types: Ito, IKslow and ISS. Ito and IKslow (Fig.
3.9) are thought to be conducted through a combination of at least three putative Kv
isoforms. Studies using transgenic mice describe that Kv4.2 is necessary for Ito; however,
there is biochemical and molecular evidence that Kv4.3 may tetramerize with it[31, 193,
254-256]. Similar studies showed that Kv1.5 and Kv2.1 both contribute to IKslow[257,
258].
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Figure 3.8: ST3Gal4-/- myocyte refractory period is significantly shorter than WT.
Action potentials were recorded in current-clamp mode and cellular refractory period was
estimated as described (n=13). A, Representative voltage traces of WT and ST3Gal4-/action potentials superimposed from independent experiments to demonstrate the
shortened refractory period in ST3Gal4-/- myocytes. B, Bar graph of cellular refractory
period in ms: WT (139.8 ± 8.6) and ST3Gal4-/- (110.2 ± 10.0); *p=0.035.

The molecular component(s) of ISS is still under debate with evidence suggesting a role
for member(s) of a two-pore domain K+ channel family, which do not exhibit any
appreciable voltage-dependence[259-262]. This can confound investigations into the
effect of a model system designed to test the role of each contributing K+ channel
isoform. One work-around that was developed and validated was to separate the kinetic
components graphically or mathematically by fitting the decaying portion of each current
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trace with a bi-exponential function (see methods)[31, 43, 78, 263, 264]. Here, this
method was employed to assess the role of ST3Gal4 in repolarizing K+ channel activity,
with a focus on Kv, in LVA myocytes using the whole-cell voltage-clamp recording
technique (Fig. 3.9).
Peak outward IK density recorded from ST3Gal4-/- myocytes was significantly
smaller at all depolarized membrane potentials from -20 mV to 50 mV (Fig. 3.10A). The
currents were then separated based on each contributing kinetic component [the rapidly
inactivating (Ito), the slowly inactivating (IKslow) and non-inactivating (ISS)].
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inactivating components (Ito, IKslow and ISS respectively). Insets include the putative
molecular correlates, representative current traces from recordings performed using
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ST3Gal4-/- Ito and IKslow demonstrated decreased current densities at smaller, nonsaturating membrane potentials compared to WT (Fig. 3.10B and C).

Conversely,

ST3Gal4-/- ISS density was smaller at more depolarized membrane potentials (30 to 50
mV) compared to WT controls (Fig. 3.10D). Cell capacitances were similar for both
groups (Table 3.2).
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Figure 3.10: ST3Gal4-/- ventricular IK is altered compared to WT controls. Here and
throughout unless noted, WT (Black circles/lines/bars; n=10) and ST3Gal4-/- (Red
diamonds/lines/bars; n=10). Data are mean ± SEM. A, Peak outward IK density is
reduced at all depolarized membrane potentials in ST3Gal4-/-. B, ST3Gal4-/- Ito density is
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The significant reduction in current density at small, but not large depolarizations,
suggests that ST3Gal4 gene deletion modulates Ito and IKslow gating. G-V relationships
were measured to determine the voltage-dependence of steady-state activation for Ito and
IKslow (Figs. 3.11A and 3.12A).

ISS conductance was not accurately described by a

Boltzmann relationship. The G-V relationships of Ito and IKslow from ST3Gal4-/- myocytes
were more depolarized than those from WT myocytes.

Boltzmann fits of the data

showed significant depolarizing shifts in Va of ~8 mV for Ito and 7 mV for IKslow from
ST3Gal4-/- myocytes compared to WT controls with no significant differences in maximal
conductance densities between groups for either current types (Figs. 3.11B and 3.12B,
Table 3.2). There was a small but significant broadening of the Boltzmann slopes from
the G-V relationships for ST3Gal4-/- Ito and IKslow compared to WT controls of
approximately 2 and 1.5 mV respectively (Table 3.2). SSI of Ito was well fit by a single
Boltzmann function and was not different between the two groups. IKslow, however, was
better fit by the sum of two Boltzmann relationships (see methods).

IKslow SSI

relationships were also not different between WT and ST3Gal4-/- myocytes (Fig. 3.13A
and B and Table 3.2).
Experiments were performed with Sialidase A as described in section 3.2 above.
Results from these studies demonstrated that enzymatic removal of surface sialic acids
caused similar differences in Ito and IKslow activation gating with significant ~7 and ~5 mV
shifts in Va, respectively, compared to untreated WT myocytes (sialidase treated: n=6;
WT: n=10; p≤0.007). These data, like those for INa, indicate that the observed effect of
ST3Gal4 gene deletion on IK is consistent with a reduction in surface sialic acids.
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Figure 3.11: ST3Gal4-/- Ito gating is shifted to more depolarized potentials with no
change in maximum conductance density. A, Steady-state activation curves of Ito
(conductance-voltage, GV relationships). B, Bar graphs of maximal conductance density.
Maximal conductance for each cell was determined by best fits of G-V data for each cell.
*p≤0.031. Lines are best fits of the data to single Boltzmann functions.
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Figure 3.12: ST3Gal4-/- IKslow gating is shifted to more depolarized potentials with no
change in maximum conductance density. A, Steady-state activation curves of IKslow
(conductance-voltage, GV relationships). B, Bar graphs of maximal conductance density.
Maximal conductance for each cell was determined by best fits of G-V data for each cell.
*p≤0.031. Lines are best fits of the data to single Boltzmann functions.
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Figure 3.13: ST3Gal4 expression does not affect Ito and IKslow SSI gating. A, Ito SSI
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describe no difference in inactivation gating. Lines are best fits of the data to single (Ito)
or double (Ikslow) Boltzmann functions. C, Representative current traces and pulse
protocol for SSI.

The rates of inactivation were determined through fitting the decaying portion of
each current trace with a bi-exponential function (see methods). The inact for Ito was not
different at any membrane potential for the two groups (Fig 3.14A and B); however, the
inact for IKslow was significantly slower in the ST3Gal4-/- myocytes at most depolarized
potentials (Fig. 3.14A and C).
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Table 3.2: The mean ± SEM IK gating parameter values

Cm
pF
WT
N=10
ST3Gal4-/N=10

163.3
±
11.1
174.3
±
20.3

Gmax/Cm
(S/F)
0.18
±
0.03
0.13
±
0.02

Va
(mV)
-3.1
±
1.1
4.7
±
1.9*

Ito
Ka
(mV)
11.7
±
0.7
13.9
±
0.4*

Vi
(mV)
-38.6
±
1.1
-37.3
±
0.6

Ki
(mV)
-4.2
±
0.5
-5.3
±
0.8

Gmax/Cap
(S/F)
0.11
±
0.01
0.09
±
0.02

Va
(mV)
-16.7
±
0.8
-9.9
±
0.9*

Ka
(mV)
7.6
±
0.3
9.0
±
0.6*

IKslow
Vi1
(mV)
-84.1
±
1.0
-84.9
±
2.3

Ki1
(mV)
-9.9
±
2.6
-7.9
±
2.0

Vi2
(mV)
-35.1
±
1.2
-34.1
±
2.1

Ki2
(mV)
-4.1
±
0.3
-5.9
±
0.4*

Cm, cell capacitance. Gmax, maximum conductance. Significance was determined using a two-tailed Student's t test or Mann-Whitney
rank sums comparing WT and ST3Gal4-/- groups. * p≤0.034.
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In addition to being distinct kinetically, the various Kv isoforms that are expressed
in mouse ventricular myocytes have varying sensitivities to pharmacological agents. For
example Kv1.5 is preferentially blocked by micromolar (μM) concentrations of 4aminopyridine (4AP) and Kv2.1 by mM concentrations of tetraethyl ammonium
(TEA)[265]. Experiments were performed to gain insight into which Kv isoforms were
affected by ST3Gal4 gene deletion. Table 5 describes the effects of 50 μM 4AP and 5
mM TEA (included in the ECS while recording from WT and ST3Gal4-/- LVA myocytes)
on Ito and IKslow activation gating and inact. Conductance voltage relationships and inact
were determined as described in the methods.
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Table 3.3: Activation gating and inact for Ito and IKslow with 4AP and TEA
Ito 50μM 4AP
Ka
inact 30 mV
(mV)
(ms)

IKslow50μM 4AP
Ka
inact 30 mV
(mV)
(ms)

Group

Va
(mV)

WT
N=8
ST3Gal4-/N=7

9.3±0.7$

11.6±0.4

35.3±1.7$

-1.5±0.9$

6.3±0.2$

1898.5±84.1$

10.1±1.7

12.7±0.8

39.6±3.5

1.5±0.4*

6.9±0.3

1744.9±87.3

Group
WT
N=7
ST3Gal4-/N=8
Group
WT
N=10
ST3Gal4-/N=10

Va
(mV)

Ito 5mM TEA
Ka
inact(30 mV)
(mV)
(ms)

Va
(mV)

Va
(mV)

IKslow 5mM TEA
Ka
inact(30 mV)
(mV)
(ms)

-3.3±1.5

11.8±0.3

52.4±3.5

-15.3±0.6

8.1±0.3

783.2±44.7&

3.9±1.1*

12.7±0.5

51.7±3.5

-13.9±0.9

7.9±0.3

808.3±27.5

Va
(mV)

Ito Untreated
Ka
inact(30 mV)
(mV)
(ms)

Va
(mV)

IKslow Untreated
Ka
inact(30 mV)
(mV)
(ms)

-3.1±1.1

11.7±0.7

58.4±4.6

-16.7±0.8

7.6±0.3

995.0±20.7

4.7±1.9#

13.9±0.4#

61.0±5.3

-9.9±0.9#

9.0±0.6#

1195.9±53.6#

Significance was determined using a two-tailed Student's t test or Mann-Whitney rank
sum test. *p≤0.012 comparing treated myocytes. #p≤0.034 comparing untreated
myocytes. $p≤0.004 comparing 4-AP treated WT myocytes to WT myocytes. &p<0.001
comparing TEA treated WT myocytes to WT myocytes.

Evidenced by the relative shifts in Va, the data suggest that Kv1.5 and Kv2.1 are affected
by ST3Gal4 gene deletion but Kv4.2 is not (Fig. 3.15 and Table 3.1). In the presence of
50 μM 4AP (which preferentially blocks Kv1.5) there is no apparent effect on Ito
activation. Contrastingly, when 5 mM TEA (which blocks Kv2.1) is used there is no
observed shift in IKslow Va but the effect on Ito remains. Interestingly, based on these data,
it would appear as though Kv1.5 contributes to both Ito and IKslow. This is supported by a
number of factors: 1) when Kv1.5 is blocked (50 μM 4AP) the Va for Ito is depolarized by
~15 mV compared to the untreated WT Va (Fig. 3.15A and Table 3.4) and 2) in the
presence of 4AP, WT inact becomes significantly faster compared to untreated WT inact at
30 mV [~35 ms (WT + 50 μM 4AP; n=8) versus ~58 ms (WT untreated; n=10; p<0.001;
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Table 5)]. In the presence of 5 mM TEA, the inact for Ito is statistically the same as
untreated WT inact, at 30 mV (Table 3.4). Additionally, when Kv1.5 is blocked with
4AP, the inact for IKslow is significantly slower and when Kv2.1 is blocked with TEA, inact
for IKslow is accelerated, both compared to untreated WT myocytes at 30 mV (Table 3.4).
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Figure 3.15: Pharmacological treatment of myocytes suggests that activation gating
of Kv1.5 and Kv2.1 are affected by ST3Gal4 expression but Kv4.2 is not. G-V curves
of Ito and IKslow comparing untreated myocytes (dashed lines, black and red) and
myocytes treated with 50 µM 4-AP (A and B), which preferentially blocks Kv1.5, and 5
mM TEA (C and D), which preferentially blocks Kv2.1 (solid lines, blue and green). A,
The effect of ST3Gal4 gene deletion on Ito activation gating is removed following 4-AP
treatment suggesting that Kv4.2 is not affected by ST3Gal4 expression but that Kv1.5 is
and that it contributes to Ito. B, In the presence of 4-AP, IKslow activation gating is
depolarized by ~3 mV suggesting that Kv2.1 is affected by ST3Gal4 expression. C, Ito
activation gating is indistinguishable between groups following 5 mM TEA treatment. D,
In the presence of 5 mM TEA, the depolarizing effect of ST3Gal4 expression on IKslow Va
is removed supporting the idea that Kv2.1 is affected by ST3Gal4 expression. * p≤0.029.
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Point 1 is supported by studies using heterologously expressed channel isoform
constructs that demonstrate a less depolarized Va for Kv1.5 compared to Kv4.2[195, 196].
Therefore, Kv1.5 may cause Ito in the mouse ventricle to also gate at less depolarized
membrane potentials as evidenced by the above mentioned data.

These findings,

however, are not conclusive and may simply be an artifact of the method employed to
delineate the current types. In mouse myocytes, Kv isoforms associate with a number of
accessory subunits that can confer changes in activity. The studies mentioned comparing
the Va of Kv1.5 and Kv4.2 were done so without the co-expression of any auxiliary
subunits. Additionally, pharmacological treatment of myocytes, which express an array
of different ion channels that may be unknowingly affected by different chemical agents,
can cause significantly confounding results including state dependent block of a number
of isoforms (including Kv4.2) that may alter channel activity[266, 267]. Moreover,
external TEA was shown to alter the inactivation of Kv1.5, which could lessen the
effectiveness of the methodology employed to delineate the current types[268]. There
were also no differences in the slopes of the Boltzmann fits in the presence of 4AP or
TEA compared to the slight broadening observed in ST3Gal4-/- myocytes without
treatment. This may be a result of incomplete block or state-dependent block of the
channels.
Together the data describe that deletion of ST3Gal4, which would likely lead to a
decrease in protein sialylation including potentially Kv, causes relative, depolarizing shifts
in activation gating of the two kinetic components of voltage-sensitive K+ current in the
mouse ventricle: Ito and IKslow. This likely involves some combination of the Kv isoforms
4.2, 1.5 and 2.1 as described above.

This phenomenon is consistent with studies
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mentioned in the introduction on the effect of desialylation of K v in expression system
studies; however, because there are multiple channel types active in cardiac myocytes
during the IK voltage-clamp protocols, the methodology employed here can only provide
a suggestion as to how the channels are affected.

Peak IK density was smaller in

ST3Gal4-/- myocytes. This was likely caused by the combination of the decrease in
current densities at non-saturating membrane potentials for Ito and IKslow, which can be
ascribed to the observed differences in G-V relationships for the two current types, and
the decrease in ISS observed at more depolarized potentials. Additionally, while not
conclusive, the pharmacological data with 4AP and TEA suggest there may be an isoform
specific effect of ST3Gal4 deletion where Kv1.5 and Kv2.1 gate differently but Kv4.2
does not. This supposition would benefit from additional studies, including different,
more specific blockers or combinations of channel blockers; however, these data are
consistent with studies describing the roles of isoform specific and regulated
glycosylation/sialylation in VGIC function. The latter may be of specific relevance when
considering that ST3Gal4 is only 1 of 20 sialyltransferases (although not all sialylate
glycoproteins) and therefore may not contribute equally to the sialylation of all K v
expressed in the mouse ventricle.

3.6. Kv isoform protein levels are differentially affected by ST3Gal4 gene deletion
Western blot analysis of sarcolemmal-enriched protein was used to determine
potential differences in expression of the various Kv isoforms between WT and ST3Gal4/-

ventricular tissue. Figure 3.16 depicts representative blots probed with antibodies

specific for the three major Kv isoforms present in mouse ventricles (Table 2.2). Optical
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densities of the protein bands were reported in AUs as described above and in the
methods section and compared to GAPDH AUs from the corresponding blots (5-13
samples/ 4-6 hearts per group). There were no differences in the protein densities of
Kv4.2 or Kv1.5 between ST3Gal4-/- and WT ventricular tissue detected (Fig. 3.16A and B.
However, a small but significant ~20% reduction in Kv2.1 expression was detected (Fig.
3.16A and B). The data suggest that ST3Gal4 may contribute to the protein/surface
expression of Kv2.1 but does not similarly affect Kv4.2 or Kv1.5. An isoform specific
effect of glycosylation on Kv trafficking and surface expression was previously
reported[269].
A

Kv4.2
WT

Kv2.1

Kv1.5

ST3Gal4-/-

WT

ST3Gal4-/-

WT

ST3Gal4-/-

~ 75 kD

~ 75 kD

~ 100 kD

~ 35 kD

B

Kv AU/GAPDH AU

~ 35 kD

~ 35 kD

1.2
1.0
0.8

*

0.6
0.4
0.2
0.0

Kv4.2 Kv1.5 Kv2.1

Figure 3.16: ST3Gal4 gene deletion reduces Kv2.1 protein expression but not Kv4.2
or Kv1.5. A, Representative western blots of Kv4.2 (left), Kv1.5 (middle) and Kv2.1
(right) along with corresponding GAPDH (bottom of each panel; ~35kD). B, Bar graph
comparing relative expression of the three Kv isoforms normalized to GAPDH expression
from WT (black) and ST3Gal4-/-(red) ventricular tissue as described in the methods.
Kv2.1 expression was reduced by ~21% in ST3Gal4-/- ventricles with no observed change
in Kv4.2 or Kv1.5. Groups compared using Student’s t test (n=5-13, at least 4 hearts per
group; *p<0.001.
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Gel-shift analyses attempting to compare sialic acid levels on the three Kv
isoforms between ST3Gal4-/- and WT ventricles were unsuccessful. Potentially, this was
caused in part by the relatively low amounts of sialic acids likely found on the channels
as will be discussed in more detail in a subsequent section. However, pilot studies
designed to quantify sialic acid levels using biochemical approaches were initiated. The
studies will attempt to exploit the reactivity of carbohydrates to oxidation by periodic
acid using dissolved sodium periodate[270]. The oxidation reaction produces reactive
aldehydes that are typically not present on proteins or the cell surface. Sialic acids can be
preferentially oxidized by performing the reaction at 4°C, in the dark and with a
relatively lower sodium periodate concentration than if attempting to oxidize all
carbohydrates[271, 272]. Following oxidation, newly formed sialic acid-aldehydes can
be labeled with derivatized hydrazides or alkoxyamines through a nucleophilic reaction
to form hydrazone or oxime bonded conjugates respectively[271, 272]. The derivatized
functional groups can include biotin or various fluorophores, which then can be detected
and quantified using protein electrophoresis or histochemical approaches. Additionally,
aniline can be used to catalyze the nucleophilic reaction increasing efficiency and
allowing for the use of more physiological solutions[271]. This methodology can be
employed to detect sialic acids on immunoprecipitated proteins as well as intact cells
using cell-impermeant alkoxyamine/hydrazide molecules. The latter being of particular
interest to question whether and how sialic acids may be distributed across the cell
membranes of cardiomyocytes. Method develop using biochemical labeling approaches
has begun and will be the focus of future experiments that are intended to investigate the
quantity and distribution of sialic acid levels on proteins or the cell surface.
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3.7. ST3Gal4 expression contributes to action potentials in mouse ventricular
myocytes
Nav and Kv play crucial roles in generating and shaping the AP. To determine
how the observed differences in Nav and Kv activity in ST3Gal4-/- myocytes would affect
APs, whole-cell current-clamp experiments were performed. In addition to INa and IK,
Ca2+ also contributes to shaping the AP via entry through Cav and release from
intracellular stores. In contrast to the cellular refractory period measurements discussed
previously, EGTA was included in the AP ICS to chelate Ca2+. This allows for the more
accurate assessment of the roles of Nav and Kv activities throughout the AP. Resting
membrane potentials were similar between the two groups; however, a number of AP
parameters were affected by ST3Gal4 gene deletion (Fig. 3.17; Table 3.4). Among these
were a longer time to AP peak, a delay in the time of the maximum rising slope and an
extension of APD at 25, 50, 75 and 90% of repolarization. There were no differences in
the maximum slope of the rising portion of the AP or in the peak amplitude between
groups.
Table 3.4: Action Potential Parameters
Group
WT
N=8
ST3Gal4-/N=9

Rm
mV

125%
Thresh
pA

TTP
ms

Max Slope
V/S

TMS
ms

APD25
ms

APD50
ms

APD75
ms

APD90
ms

-71.1±0.9

736.3±35.8

10.5±0.3

103.6±14.8

9.9±0.2

9.1±0.5

11.6±1.0

16.4±1.9

25.8±3.0

-69.7±0.7

586.3±63.6

12.3±0.5*

95.8±11.8

11.7±0.5*

11.1±0.6*

15.1±1.0*

21.8±1.5*

36.9±2.3*

Rm, resting membrane potential. 125% Thresh, 125% of the threshold current. TTP,
time to AP peak. Max Slope, maximum rising portion of AP. TMS, time of max slope.
Significance was determined using a two-tailed Student's t comparing WT and ST3Gal4-/groups. p≤0.045.
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Figure 3.17: Time to action potential peak and action potential duration are altered
in ST3Gal4-/- myocytes compared to WT controls. A, Representative voltage traces
from ST3Gal4-/- (red) and WT (black) myocytes. B, Bar graphs describing WT (black,
n=9) and ST3Gal4-/- (red, n=8) action potential parameters. Rm, resting membrane
potential. Peak, maximum action potential amplitude. TMS, time to reach the maximum
rising slope. TTP, time to peak of action potential. APD, action potential duration at 25,
50, 75 and 90% of repolarization. *p≤0.045.
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3.8. ST3Gal4-/- hearts are more susceptible to ventricular arrhythmias
The measured decrease in ventricular myocyte refractory period and/or the
alterations in AP waveforms (Figs. 3.8 and 3.17) could be pro-arrhythmogenic. To
question whether the ST3Gal4-/- ventricles were more susceptible to aberrant conduction,
we studied and compared conduction across the epicardium of ST3Gal4-/- and WT left
ventricles using optical mapping techniques as described. The mean refractory period
was a significant ~23 ms shorter for the ST3Gal4-/- left ventricles compared to WT
(ST3Gal4-/-, 59.5 ± 5.5 ms; WT, 82.4 ± 6.8 ms; n=11, p<0.01). Conduction velocity was
slightly, but insignificantly slower along the ST3Gal4-/- epicardium (ST3Gal4-/-, 0.57 ±
0.04 m/s; WT, 0.62 ± 0.03 m/s; p = 0.31). Following determination of the refractory
period, ventricles were stimulated with 2-6 suprathreshold 2 ms pulses at intervals 5 ms
longer than the measured refractory periods (pacing protocol). The stimulation protocol
had little effect on WT conduction (Fig. 3.18A and C); only one WT ventricle displayed
any type of aberrant conduction, a modest ventricular tachycardia (Fig. 3.18A and C).
However, nearly 75% of the ST3Gal4-/- hearts tested showed some significant aberrant
conduction (Fig. 3.18A). The observed arrhythmic behavior (Fig. 3.18B and C) included
ventricular tachycardia (in 62.5% of arrhythmic ST3Gal4-/- ventricles), reentry (25%),
afterdepolarizations (12.5%), and ventricular fibrillation (25%).

In the ST3Gal4-/-

ventricles, such arrhythmias were observed typically after only two or three pulses, while
up to six stimulating pulses did not induce any type of arrhythmic behavior in 91% of
WT ventricles tested. Examples of the typical impact of the pacing protocol on WT and
ST3Gal4-/- ventricles are shown in Fig. 3.18C. These data strongly suggest that the
ST3Gal4-/- ventricle is more susceptible to aberrant conduction. This is consistent with
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both the faster Nav channel recovery from fast inactivation that likely contributes to
shorter cellular and epicardial refractory periods and the altered AP waveforms, including
the extension of APD that may contribute to afterdepolarizations.

3.9. Electrocardiograms from ST3Gal4-/- hearts demonstrate a slowing of heart rate,
aberrant conduction and suggest a reduction in repolarization reserve
To test whether the differences in channel function and cellular electrical
signaling as well as the apparent increased susceptibility to arrhythmias in the left
ventricular epicardium observed in ST3Gal4-/- mice could affect cardiac conduction under
normal physiological conditions, ECGs were recorded from conscious unrestrained
animals. Mean heart rates were significantly slower in ST3Gal4-/- mice and displayed
more variability. Concurrent with this was a consistent lengthening and dispersion of the
P wave and RR interval (Fig. 3.19A and B). In addition to a slower heart rate, four of the
nine ST3Gal4-/- mice demonstrated aberrant conduction events that included premature
ventricular contractions and irregular spacing between systoles (Fig. 3.19C). None of the
nine WT animals displayed any type of apparent conduction anomalies.
Because the heart can demonstrate significant conduction/repolarization
reserve[273, 274], which can potentially mask variations in conduction under normal
conditions of cardiac function, additional preliminary experiments were performed in an
attempt to determine potential differences in response to a cardiac "challenge" between
ST3Gal4-/- and WT animals.
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Figure 3.18. ST3Gal4-/- ventricles are more susceptible to arrhythmias. Left
ventricular conduction in WT and ST3Gal4-/- hearts was studied using optical mapping
methods as described (n=11). A, Percentage of ventricles displaying at least one type of
arrhythmia. The single WT (black) ventricle showing arrhythmic behavior displayed
modest V. Tach. B, Percentage of arrhythmic ST3Gal4-/- ventricles presenting with one
of four types of ventricular arrhythmias (see methods). C, Representative data from a
single WT (panels 1, 2) and ST3GAl4-/- (panels 3, 4) heart. 1 and 3, Activity following
two stimulating pulses at intervals ~2X the measured refractory period. 2 and 4, Activity
following 5 (WT, panel 2), and 3 (ST3Gal4-/-, panel 4) stimulating pulses at intervals 5
ms longer than the measured refractory period. Figure generated by Jiashin Wu and used
with permission. Figure created by Jiashin Wu and used with permission.
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Figure 3.19: Electrocardiograms from ST3Gal4-/- and WT mice suggest altered
cardiac conduction and rhythm. A, 1 second sampling of ECGs recorded from two
ST3Gal4-/- mice (KO, black and blue, top two) and one WT mouse (control, green,
bottom) demonstrate slowed heart rates in ST3Gal4-/- mice. B, enlarged view of P and
QRS segments from the same mice. The P and RR intervals are lengthened in the two
ST3Gal4-/- mice compared to WT controls. C, Apparent premature beat observed in an
ECG from a ST3Gal4-/- mouse. Such arrhythmias occurred consistently in ST3Gal4-/mice but at irregular intervals. Similar arrhythmic events were not observed in any WT
mice.
A low dosage (8mg/kg) of the β-adrenergic agonist isoproterenol, which demonstrates
positive chronotropic and ionotropic effects on the heart[275], was administered
intraperitoneally to ST3Gal4-/-(n=2) and WT (n=1) groups (Fig. 3.20).

Following

administration of isoproterenol, both of the ST3Gal4-/- animals demonstrated marked
changes in ECG waveforms that began with early sinus bradycardia with ST elevation
followed by ST depression and apparent QT prolongation. A previous study utilized a
similar dosage and too reported no effect on WT mice[276]. 24 hours later the ECGs for
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both groups were normal. Isoproterenol was again administered and produced similar
effects on both ST3Gal4-/- animals whereas, again, did not affect the WT. Following this
second treatment, ECGs from the ST3Gal4-/- mice only marginally recovered even after
48 hours at which point the animals were euthanized. The results obtained from the
isoproterenol experiments suggest that ST3Gal4-/- mice are more susceptible to βadrenergic stimulation that may be related to a reduction in repolarization reserve. While
extremely preliminary given the low sample numbers and the lack of specificity of
isoproterenol treatments, these data are provocative and consistent with the observed
differences in ST3Gal4-/- Nav and Kv activity as well as the extension of APD that all may
contribute to reduce repolarization reserve. However, since the transgene is globally
expressed, the data do not rule out a number of other possible explanations for the
heightened response to isoproterenol that may include aberrant autonomic innervation, a
potentiated effect on nodal cells or an increased sensitivity to isoproterenol by βadrenergic receptors in the ST3Gal4-/- mice. There is evidence that adrenergic receptors
are sialylated and that sialic acids may influence the binding of certain
agonists/antagonists[277-279]. Additionally, isoproterenol may acerbate any potential
differences in neuronal regulation of the heart caused by ST3Gal4 gene deletion possibly
related to effects on neuronal VGICs. Preliminary studies were also performed on left
ventricular epicardiums using optical mapping methods following isoproterenol treatment
delivered through the perfusate. Data from these experiments require analysis; however,
a heightened effect on ST3Gal4-/- ventricular epicardiums, similar to those observed
through ECG recordings, may help determine the site of apparent potentiated action of
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isoproterenol on the ST3Gal4-/- mice. Cellular studies may also be performed to ascertain
if the effect in found at the myocyte level.
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conduction with little to no effect on WT. Results of ECG telemetry experiments on
ST3Gal4-/-mice (top KO1 and middle KO2) and WT (bottom) following an
intraperitoneal injection of isoproterenol (8mg/kg). Marked changes in cardiac
conduction were observed in both ST3Gal4-/- mice suggesting a possible reduction in
repolarization reserve consistent with the AP and IK data.
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Chapter 4
Discussion

4.1. ST3Gal4 gene deletion directly alters Nav sialylation and gating and myocyte
refractory period
Here we demonstrate that deletion of the ST3Gal4 gene causes significant
changes in ventricular Nav gating and activity, but does not impact Nav surface
expression or maximal current density (Figs. 3.1 - 3.4 and 3.6). Small, but uniform and
significant shifts in the voltage-dependence of steady-state activation and inactivation
gating were observed. The shifts in gating, while uniform, will likely cause opposing
effects on electrical excitability. A rightward shift in Nav activation voltage will cause a
loss-of-function because channels will require a greater depolarization to activate. A
missense mutation (R282H) in the human Nav1.5 gene (SCN5A) discovered in a family
pedigree was linked to Brugada-like ECG characteristics including a coved and elevated
ST segment and nocturnal syncope due to polymorphic ventricular tachycardia[280].
Expression system studies of the mutated gene product showed a depolarizing shift in Va
of ~5 mV similar to the shift observed in this study. There are a number of other
examples were congenital defects in SCN5A cause relatively small depolarizing shifts in
Va[281-283]. These shifts, parallel to that observed from ST3Gal4-/- mice Nav, may
contribute to dangerous phenotypes consistent, in terms of ECG properties, with Brugada
syndrome.

Conversely, a depolarizing shift in Vi would render fewer inactivated

channels at a given membrane potential: a gain of Nav function, which was linked to
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LQT3 and other isolated conduction diseases[284-288]. A rightward shift in both steadystate events results in a depolarization of the window current, which may lead to
increased excitability[70], and is also associated with LQT3[286, 289]. In agreement
with a rightward shift in activation voltage, we observed a slowing of fast inactivation at
hyperpolarized potentials. Slower fast inactivation can manifest as a gain of Nav function
and cause life-threatening arrhythmias[70, 289, 290]. Because the portion of the AP
where “persistent” INa, originating from a slowing of fast inactivation, would be
conducted is controlled by a delicate balance of ionic flux, only a marginal increase in
current is necessary for arrhythmogenesis[290-292]. In fact, persistent current as little as
1-5% of the maximum current can cause an extension of the AP that may lead to
significant arrhythmias[291, 293]. Additionally, many SCN5A mutations demonstrate
multiple phenotypes that are associated with both losses- and gains-in-function when
studied in expression systems; concurrent with this, patients harboring these mutations
can present with multiple ECG lesions[294-296]. These combinatory Nav phenotypes are
similar to those which are described here for ST3Gal4-/- Nav. Thus, the influence of sialic
acid on Nav gating and fast inactivation is confounding and may contribute opposing
effects on myocyte excitability. However, consistent with a rightward shift in activation
and a slowing of fast inactivation, the data here describe a slowing of the time to AP peak
and the time of maximum AP slope with no change in peak amplitude or maximum AP
slope. Additionally, the slowing of fast inactivation is a substrate for "persistent" INa that
may contribute to the observed extension of APD particularly at 25 and 50% of
repolarization (Figs. 3.4 and 3.17)[297].

98

Data from the biochemical experiments using sialidase A suggest that there are
fewer sialic acid residues on Nav from ST3Gal4-/- ventricles than are attached to Nav
expressed in WT ventricles (Fig. 3.7). Interestingly, while the depolarizing shifts in
activation and inactivation described here were consistent with previous reports, the
magnitudes of the shifts were smaller than those of other studies where shifts of 7-8 mV
were observed[177, 178]. While both previous studies were performed using a different
experimental system than was used here, one might still predict that, in the previous
studies, the amount of (functional) sialic acid removed from Nav (using prolonged
incubation with neuraminidase at an elevated temperature) or prevented from being
attached to Nav (with the deletion of a polysialyltransferase gene) was greater than that
observed here for the untreated ST3Gal4-/- myocytes. If so, then this could explain the
smaller sialic acid dependent shift observed for ST3Gal4-/- Nav gating. The present
model differs in that ST3Gal4 is only 1 of 20 sialyltransferases that adds a single sialic
acid to a specific glycans; therefore it is reasonable to assume, based on this and the
biochemical data, that ST3Gal4 is only one component in a complicated process whereby
glycosylation contributes to electrical signaling. This and the previous reports support
the idea that sialylation affects Nav gating through a saturating mechanism; whereby, as
the number of functional sialic acid residues increases so too does the hyperpolarizing
effect on the channel’s voltage-dependent gating properties. Additionally, together, and
consistent with previously reported data[175-179, 184, 214], the biophysical data (Figs.
3.2 - 3.4) for less sialylated Nav, combined with the biochemical data (Fig. 3.7), strongly
suggest that at least some of the effects of ST3Gal4 gene deletion on Nav function are
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likely mediated directly via a decrease in the number of functional sialic acids attached to
Nav  subunits.
An important contribution of Nav activity to cardiac conduction is the time needed
for channels to recover from fast inactivation. Recovery from fast inactivation is a
voltage-dependent process involving the movement of the S4 region of domain IV[298,
299] and therefore would likely be affected by a reduction in negatively charged SA
residues from the external electric field. Here we report that deletion of ST3Gal4 causes
~23% increase in the rate of recovery from fast inactivation of Nav (Fig. 3.5). A similar
change in channel function was observed among a group of mutations in SCN5A[300].
These mutations are well conserved within a number of familial cases of idiopathic
ventricular fibrillation (IVF), which are associated with life-threatening heart rhythm
disturbances[300]. In fact, the degree of increased recovery rate for ST3Gal4-/- Nav
observed here is more dramatic than that shown previously to be associated with IVF.
SCN5A mutations that cause an acceleration in recovery from fast inactivation present a
significant gain-in-function. There are a number of these mutations that are associated
with LQT3 and increase the rate of recovery from fast inactivation anywhere between 29
to 65% of the WT channel in expression system studies, although some of these protocols
were performed at different membrane potentials ranging from -120 to -90mV making
them difficult to compare[286, 287, 301-303]. An acceleration in recovery from fast
inactivation of Nav would likely have two major effects on the AP.

Because the

probability of a channel reopening as the membrane repolarizes would be increased, an
increase in recovery rate could extend the duration of the AP, which was observed in
ST3Gal4-/- ventricles (Fig. 3.17). Additionally, an acceleration in recovery may decrease
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the time needed for a second AP to fire, or the cellular refractory period. To test whether
the acceleration of Nav recovery from fast inactivation affects cellular conduction, we
estimated the myocyte AP refractory period, finding that the refractory period is
shortened by a significant ~21% in ST3Gal4-/- myocytes, consistent in magnitude and in
predicted impact, with the observed acceleration of recovery from fast inactivation for
ST3Gal4-/- Nav (Fig. 3.8).
Based on the data presented here and in other studies investigating the effects of
sialic acids on Nav activity, it seems that relatively modest changes in the external
electrical field (although the exact magnitude is not known), which would likely occur
following a reduction in sialic acids, significantly affects channel function.

This

alteration in the external electric field likely influences the manner in which the channels
gate leading to changes in function that mimic those caused by mutations in SCN5A that
are associated with aberrant conduction. It is interesting to note that, in humans, these
marginal shifts in Nav function are associated with significant arrhythmias (although
there is rarely a direct link demonstrated); however, there is no gross cardiac phenotype
in the ST3Gal4-/- mouse.

A likely explanation for this is that the mouse heart

demonstrates little susceptibility to arrhythmia likely because of its rapid rate and lack of
significant variability in rate[47]. The human heart rate, on the other hand, will display
striking variability in rate based on stimuli and different physiological settings (sleep,
exercise, etc.).

Many patients that suffer from Brugada syndrome, LQT or other

conduction disorders associated with mutations in SCN5A often experience the most
dramatic symptoms during sleep/relaxation, exercise or even fever when heart rate is
altered or the body temperature is raised[280, 281, 283, 304-306]. In fact, in many cases
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the ECG symptoms in humans are only revealed following exercise or pharmacological
intervention[307-309]. These dynamic changes in heart rate likely occur less frequently
in mice. Therefore, under normal conditions, the observed differences in ST3Gal4-/- Nav
function likely do not contribute to significant alterations in cardiac excitability that
would cause a gross phenotype including unexplained/sudden death or shortened life
spans.

4.2. Deletion of ST3Gal4 causes specific non-uniform effects on IK and KV expression
The data presented in this report indicate that deletion of ST3Gal4 has a
significant impact on repolarizing K+ currents. Peak IK density recorded from ST3Gal4-/myocytes was smaller at all test potentials compared to WT controls (Fig. 3.10).
Dissection of the current into three kinetic components indicated a range of effects. Ito
and IKslow densities from ST3Gal4-/- myocytes were smaller at less depolarized potentials
than WT but similar at larger ones (Figs. 3.10B and C). In agreement with the idea that
this would likely be caused by depolarizing shifts in activation gating for each of the two
kinetic current types, G-V relationships and Va were both depolarized for Ito and IKslow
with no difference in maximal conductance density for ST3Gal4-/- myocytes (Figs. 3.11
and 3.12). Western blotting of sarcolemmal enriched protein indicated similar expression
for Kv4.2 and Kv1.5 protein. There was a small but significant ~20% reduction in Kv2.1
protein from ST3Gal4-/- ventricular tissue. ISS density was decreased at depolarized
voltages (Fig. 3.16). Following treatment of WT and ST3Gal4-/- myocytes with 5 mM
TEA (which blocks Kv2.1) no differences in ISS densities were detected suggesting that,
while utilizing this methodology to delineate the different K+ current types, Kv2.1 may
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contribute to ISS biophysically although likely not molecularly.

If the decrease in

ST3Gal4-/- Kv2.1 protein contributed to the reduction in ISS density how could deletion of
the ST3Gal4 gene cause this?

There is evidence that the desialylation of glycan

structures of ion channels affects surface retention and internalization by unmasking
binding sights of carbohydrate binding proteins galectins[210, 213].

Additionally,

neuraminidase treatment of isolated cardiac myocytes caused a reduction in IK
density[194]. This is in contrast to results from this study and others investigating Nav
activity following enzymatic desialylation or genetically mediated reductions in
glycoprotein sialylation where there has been no reported effect on current density or
surface expression. Perhaps sialylation imparts an additional effect on Kv relating to
trafficking and internalization of the proteins that differs from that of Nav. Also unlike
the effect of sialic acid on Nav were the non-uniform shifts in SSA and SSI. While
ST3Gal4-/- Ito and IKslow demonstrated 8 and 7 mV shifts in Va and G-V relationships,
respectively, compared to WT controls, voltage-dependent inactivation was not affected
by ST3Gal4 gene deletion as evidenced by the lack of significant differences in SSI
relationships and Vi between the two groups (Fig. 3.13 and Table 3.2). These findings
are consistent with previous reports in that sialic acid has a non-uniform effect on Kv
gating where activation is effected but inactivation is not[195, 196]. This suggests a
difference in the coupling between voltage-dependent activation and inactivation in Kv
compared to Nav, which have consistently demonstrated uniforms shifts in both voltagedependent activation and inactivation following desialylation. There is also evidence that
sialic acids (or perhaps glycosylation in general) may affect Kv activity through
mechanism that do not involve electrostatic interactions[310, 311]. The slopes of the
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Boltzmann fits for Ito and IKslow activation were broadened in the ST3Gal4-/- myocytes
(Table 3.2).

A similar finding was made by Watanabe et al., as described in the

introduction[310]. The grouped hypothesized that glycans confer an additional effect on
channel gating likely caused by their influence on protein stability and the movement of
domains during gating. Also in support of this is the finding that the effect of ST3Gal4
gene deletion on fast inactivation of IKslow did not demonstrate any appreciable voltagedependence suggesting perhaps a non-electrostatic mechanism (Fig. 3.14B).

Kv1.5,

which putatively contributes to IKslow, inactivates through C-type inactivation, which is
generally not considered voltage-dependent, although in native tissue an additional Ntype inactivation is conferred likely through the actions of the β subunit Kvβ1.3; however,
this is typically only observed at near-physiological temperatures[268, 312]. Kv2.1 is
also thought to contribute to IKlsow and has been described as having U-shaped
inactivation, which is a novel type of channel inactivation that can be described as having
multi-phasic responses to voltage, although the physiologic consequence of U-type
inactivation is poorly understood[313]. A slowing of inactivation would likely contribute
to longer K+ efflux and would confer a gain-in-function.
Repeated attempts to compare the relative levels of sialylation on the various K v
isoforms from ST3Gal4-/- and WT ventricular tissue were unsuccessful. No appreciable
shifts could be detected following enzymatic desialylation and western blotting, which
was effective in comparing the extent of sialylation on Nav between the two groups. This
could be ascribed to the lack of sensitivity of the assay in detecting minor shifts in
molecular weight and the fact that Kv are likely less glycosylated/sialylated compared to
Nav. Kv4.2 and Kv2.1 are only O-glycosylated and Kv1.5 has one putative N-linked
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site[195, 196] compared to the 13 potential N-linked sites found on Nav1.5[175].
Additionally, because Kv are tetramers, desialylation would affect the relative MW 1/4 as
much as it would if they were one polypeptide as is the case with Nav. It is interesting to
note that while it appears as though the extent of glycosylation/sialylation is greater for
Nav, the shifts in Va for Ito and IKslow were of greater magnitude. One intriguing possible
explanation for this is that the likely smaller glycan structures, particularly for O-linked
Kv, may place the functional sialic acids in closer proximity to the voltage sensing
machinery thereby exerting greater effects on gating. Additionally, there is evidence that
brain Kv isoforms have atypical internally linked sialic acids that would also likely be
closer to the voltage-sensing portion of the channels than those terminally attached[189].
The observed effects of ST3Gal4 gene deletion on the activity of Kv in mouse
.myocytes could have a significant effect on cellular and cardiac electrical excitability,
which is supported by the AP, optical mapping and ECG data. A rightward shift in
activation gating with no effect on inactivation gating, which was observed for Ito and
IKslow, would reduce the area of the window current. Such a change could decrease the
effective IK density. A reduction of IK is the major contributor in LQT syndromes 1,2,5
and 6[314]. While it is important to note that the Kv isoforms responsible for these
diseases differ than those found in the mouse ventricle, the observed effects on the AP
and ECGs should generally be conserved.

Additionally, both Kv1.5 and Kv2.1 are

expressed in the human atria[315] indicating that diseases of glycosylation, which could
affect the human isoforms in manners similar to those observed here, may have important
ramifications on human atrial excitability or other tissues that express these channels.
Kv1.5 is an important mediator in atrial fibrillation, which is the most common clinical
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arrhythmia. A down regulation of IK density and Kv1.5 protein expression were observed
in patients with atrial fibrillation[315]. Subsequent studies have shown that congenital
defects in the Kv1.5 gene cause losses-in-function that reduce current[316, 317]. An
effective reduction in current, as described here originating from aberrant sialylation,
could cause a similar pathology as that observed in patients with atrial fibrillation. The
predominate human ventricular Kv isoforms are Kv7.1 and Kv11.1[30, 42]. Kv7.1 (also
referred to as KvLQT1) co-assembles with the auxiliary subunit minK to conduct the IKs
current in the human ventricle.[318]. There are at least four mutations in the KvLQT1
gene associated with LQT, Romano–Ward or Jervell and Lange–Nielsen syndromes, that
demonstrate positive shifts in Va when studied in expression system, with three of the
mutations requiring the co-expression of minK to demonstrate the observed shifts[319,
320]. The functional result of these mutations is consistent with the effect of reduced
protein sialylation on Kv reported here. Gating of the KvLQT1-minK complex was also
shown to be directly affected by protein glycosylation[321]. Expression in the Lec-1
CHO cell line, which does not produce complex N-glycans and therefore cannot form Nlinked glycan structures that contain terminal sialic acids, shifted the Va by ~7mV
compared to expression in the fully glycosylating Pro5 cell line, but only when both
subunits were expressed. While the authors were not investigating the effect of sialic
acids directly, these data imply that KvLQT1 does not possess functional N-linked sialic
acids but those found on the minK subunit can influence gating of the native channel
complex. Interestingly, when the pH was lowered, the Va of KvLQT1 expressed alone, in
both cell lines, was depolarized suggesting that the channel may possess functional Olinked sialic acids that were masked when the solution was acidified thereby shifting
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gating as if sialic acids were removed. However, these results do not rule out a direct
effect of lower pH on channel gating. More recently, a report described stark differences
in the effect of deglycosylation on the minK subunit and the subsequent current produced
by co-transfection with KvLQT1 than those previously mentioned[322].

The study

described two N-linked glycosylation sites and one O-linked glycosylation site within the
N-terminus of the minK subunit. When mutants that lacked the various glycosylation
sites were co-expressed with KvLQT1, no differences in Va were observed; however,
there was a significant slowing of deactivation kinetics in both of the N-linked mutants.
It is difficult to reconcile these two contrasting reports. The only reasonable explanations
are that the constructs used in the two studies differed in the number of glycosylation
sites (the study using the glycosylation mutants focused on a discreet portion of the Nterminus while the other study utilized CHO cell mutants that lack a glycogene that is
necessary for the formation of sialic acid-linked N-glycans and did not mutate any
potential glycosylation sites from minK or KvLQT1) or because of a difference in the
manner in which the measurements were performed. However, it is interesting to note
that in the more recent study, where no effect on Va was observed, the authors described a
co-dependence of glycosylation sites in producing the mature surface expressed KvLQT1minK complex. When O-linked glycosylation was prevented through mutagenesis, all Nlinked glycosylation was blocked causing essentially none of the protein complex to
reach the membrane surface. Because glycosylation is a sequential process beginning in
the ER and continuing throughout the Golgi, these results demonstrate that the concerted
actions of many glycogene products are necessary for proper protein processing. Defects
in one step of the glycosylation process can have deleterious effects on others. Improper
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protein trafficking, via aberrant glycosylation, was linked to human arrhythmias or
diseases of aberrant excitability that involve both minK/KvLQT1 and Kv11.1 (hERGproduct)[323-328]. These mutations cause a reduction in current density due to fewer
channels at the surface, which then delays repolarization and extends the QT interval.
Contrastingly, in a number of expression system studies, mutations that removed Nlinked glycosylation sites did not cause any appreciable differences in current densities,
and therefore the likely surface expressions, of Kv1.4, Kv1.5, the drosophila shaker K+
channel homolog as well as the hERG-product[191, 195, 250] although since the genetic
material was not titrated, this may simply be an artifact of over-expression. Additionally,
sialic acids also have a hyperpolarizing effect on the gating of the hERG-product[250].
However, because of the unique kinetics of the channel[329], it is likely that depolarizing
shifts in gating following a reduction in functional sialic acids would cause a gain-infunction and shorten the AP. Modeling experiments utilizing the data have confirmed
this and describe the shortening of the AP as well as a distortion of cardiac conduction
following reductions in sialic acids in silico[330].
How is it possible that myocytes from ST3Gal4-/- mice demonstrate a decrease in
peak IK density but the maximum conductance densities for Ito and IKslow are not different
between the groups? This is in stark contrast to the effect of ST3Gal4 gene deletion on
INa where no change in maximum current density was observed and activation gating was
depolarized. As described earlier, one explanation is that the decrease in current densities
of Ito and IKslow at smaller, non-saturating potentials (likely due to the positive shifts in the
G-V relationships) and the decrease in ISS at saturating potentials, which may be related
to the small but significant reduction in Kv2.1 protein, cause an overall reduction in
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current at each test potential. However, it is interesting to consider another possibility
related to the inherent differences in the biophysical properties of Nav and Kv channels.
Typically, Nav inactivate completely on the order of a few ms and the conductance is
quickly saturated. Contrastingly Kv inactivate more slowly and therefore an individual
channel will “experience” a voltage during a pulse protocol or AP for a longer interval.
During this interval, there is an equilibrium among individual channels between an open
and closed state. If channel gating is stochastic and the probability that a channel is open
at a non-saturating voltage is decreased (as demonstrated by a rightward shift in the G-V
relationship) then it is likely that fewer channels would be open within a population of
similar channels compared to a population of channels where the G-V relationships are
relatively hyperpolarized. This along with a reduction in the area of the window current
as described above would likely act to decrease the effective IK density, particularly over
the voltage-range of a typical AP. Regardless of the exact mechanism, functionally the
data demonstrate this by the observed reduction in peak IK density/voltage relationships
and the extension of the AP in ST3Gal4-/- myocytes; although, the effects on the AP may
also involve differences in Nav function. In support of the idea that depolarizing shifts in
gating may affect the effective current density of a Kv, previous reports have described a
reversible electrostatic-mediated modulation of Kv gating by administration of positively
or negatively charged fatty acid derivatives[331-333]. The impetus for these studies was
based on the fact that polyunsaturated fatty acids have a beneficial effect on epilepsy and
arrhythmias[334, 335]. In subsequent studies the authors incorporated some of the data
into computer modeling experiments where they determined that a rightward shift of 5
mV in Va can decrease the effective K+ channel density as well as increase the chance of
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repetitive AP firing both by 3 fold[332]; although, the model system was that of a
myelinated frog axon where only one Nav and one Kv contribute to the AP. In spite of
this, these studies offer insight into the role of electrostatic-mediated effects of Kv gating
and on cardiac electrical signaling. Reported here are data consistent with these findings
as described by the decrease in peak IK density and the extension of APD as well as the
decrease in myocyte refractory period in ST3Gal4-/- myocytes. Typically, mutations in
Kv genes that are associated with human diseases such as various LQT syndromes are
associated with reductions in channel and current densities[336-339]. In addition to
congenital diseases that reduce Kv surface expression thereby extending the AP, there are
numerous examples of acquired pathologies that cause a reduction in IK and extend the
AP[228, 340-342]. A reduction in Ito, which in humans is associated with reduced Kv4.3
protein or the auxiliary protein KChiP, is often an important contributor to this process or
is observed in disease models that attempt to investigate the mechanisms behind such a
reduction[341, 343-345]. Much like an increase in “persistent” INa, a reduction in Ito
affects the AP during a phase where only marginal changes in ionic flux can significantly
increase the APD leading to an extension of the QT interval. We observe here that
deletion of the ST3Gal4 gene causes changes in IK that, functionally, mimic those
associated with acquired and/or congenital diseases that cause Kv associated electrical
remodeling without a significant change in Kv protein expression (other than the apparent
20% reduction in Kv2.1 protein in ST3Gal4-/- ventricular tissue) .

Moreover, the

reduction in IK density, which likely, at least in part, contributed to the extension of APD,
could lead to a reduction in repolarization reserve. This is consistent with the ECG data
following isoproterenol treatment whereas the ST3Gal4-/- mice demonstrated a
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significantly lower threshold for aberrant conduction following a cardiac “challenge.”
Repolarization through Kv is considered an important mediator in the maintenance of
repolarization reserve in humans[346-348].

4.3. ST3Gal4 is a substrate for arrhythmias
If the reduction in myocyte refractory period, slowing of cellular conduction and
the extension of APD are relevant to ventricular electrical signaling, one might predict
that the ST3Gal4-/- ventricle would be more susceptible to arrhythmias. The optical
mapping data show a significant 27% reduction in minimum refractory period and a clear
increase in arrhythmic behavior in the ST3Gal4-/- ventricle. Arrhythmias were observed
in

nearly

75%

of

the

ST3Gal4-/-

ventricles,

with

reentrant

conduction,

afterdepolarizations and/or ventricular fibrillation observed in >60% of the affected
ventricles. This susceptibility to arrhythmias is consistent with that predicted for a
significantly reduced myocyte refractory period in which aberrant conduction would be
expected to occur more frequently, potentially leading to ventricular fibrillation.
Additionally, the differences in ST3Gal4-/- myocyte AP waveforms, which may be
attributed to both the changes in Nav and Kv function, could contribute to the reentry and
afterdepolarizations

observed

in

ST3Gal4-/-

ventricular

epicardiums

following

stimulation. Delayed repolarization is an important mediator in LQT syndromes where it
is thought that the delay in repolarization can increase the heterogeneity of refractory
periods among neighboring myocytes. This dispersion in refractory periods can then lead
to afterdepolarizations and the specific type of reentrant arrhythmia: torsade de pointes
[60, 349]. In LQT3, an increase in APD can be associated with mutation in SCN5A that
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demonstrate an increase in “persistent” INa, caused by the slowing of fast inactivation, and
in an increase in the rate of recovery from fast inactivation[287, 301-303, 350]. More
commonly, however, decreases in repolarizing K+ current associated with mutations in
Kv genes are associated with the LQT phenotypes[42, 60, 71, 351-353].

Here, in

myocytes from ST3Gal4-/- mice, we see differences in Nav and Kv channel activity that
parallel those of channel mutations associated with LQT syndromes. Patients afflicted
with the various LQT syndromes present with ECG lesions consistent with the
arrhythmias observed in the optical mapping experiments following stimulation. Based
on the observed cellular data it is likely that the greater susceptibility to arrhythmias in
the ST3Gal4 ventricular epicardium is due to some combinatory effect of aberrant Nav
and Kv function.

Future optical mapping studies will be performed utilizing

pharmacological approaches to block specific channel types in an attempt to discern if
and how each channel type contributes to the observed arrhythmias.

Additionally,

because reentrant arrhythmias associated with LQT-induced afterdepolarizations often
involve Ca2+ influx due to reactivation of Cav before complete repolarization of the
AP[349, 354], optical mapping approaches will also be used in future experiments to
determine if differences in Ca2+ handling exist between WT and ST3Gal4-/- ventricles.
ECG recordings under basal conditions demonstrated only modest differences
between groups. Heart rates were slower in ST3Gal4-/- mice, which is consistent with a
slowing of cellular conduction and a loss-of-function in Nav, and demonstrated greater
variability. The duration of the P wave was extended in ST3Gal4-/- ECGs suggesting an
effect of atrial conduction. Unpublished data from this lab demonstrated shifts in Kv
gating and an extension of APD in ST3Gal4-/- neonatal atrial myocytes compared to WT
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controls.

Progressive cardiac conduction disease, which is characterized by a

prolongation in conduction in the form of extended P, PR and QRS waveforms with no
change in ST segment or QT interval, was associated with loss-in-function mutations in
SCN5A that, when studied in expression systems, displayed phenotypes analogous to the
positive shift in Va observed for ST3Gal4-/- Nav[355-357]. No discernible differences in
QT segments were detected between the two groups in contrast to the observed
differences in cellular and epicardial electrical signaling observed in ST3Gal4-/ventricular myocytes and ventricles. One possible explanation may be related to the
inherent

and

likely

greater

redundancy

present

in

mouse

cardiac

conduction/repolarization compared to that found in human cardiac function as described
in a previous section. This redundancy could potentially mask aberrant conduction in the
ST3Gal4-/- mice. As is often performed with humans to diagnose arrhythmias, ECG
recordings of ST3Gal4-/- and WT mice following administration of channel blockers will
be performed in future experiments in order to attempt to uncover a more obvious
pathological ECG phenotype in the ST3Gal4-/- mice. There was, however, a qualitatively
observed increase in aberrant conduction in ST3Gal4-/- mice ECGs, which was not
observed in any WT mice, that included premature ventricular contractions, which is
commonly associated with torsade de pointes[349]. It is also important to note that ECG
parameters were difficult to measure, particularly QT segments, using these experimental
conditions and latent differences may still exist. Because the mice were ambulatory,
there was a significant amount of noise associated with the telemetry recordings that
decreased the ability of the software to identify and quantify the pertinent ECG
parameters. Studies are planned to perform surface ECGs on anaesthetized mice and on
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Langendorff hearts. Potentially, results from these studies will uncover differences in
ventricular electrical signaling in the form of altered QT segments that are consistent with
the cellular and epicardial data. In spite of the lack of any significant ECG phenotype, it
is interesting to consider the possibility that the alterations in Nav and Kv function, caused
by ST3Gal4 gene deletion, may manifest as overlapping syndromes. Under conditions of
basal cardiac function, ST3Gal4-/- ECGs are characterized by a slowing of conduction
consistent with disorders that include progressive cardiac conduction disease or Brugada
syndrome.

Following stimulation, however, ST3Gal4-/- mice present with a distinct

phenotype consistent with LQT as demonstrated by the optical mapping studies and the
ECG recordings performed following administration of isoproterenol. There are SCN5A
mutations that are associated with similar overlapping phenotypes[295, 296, 358].
Additionally, ECG patterns from ST3Gal4-/- mice following isoproterenol treatment were
consistent with those typically observed in patients with LQT syndromes and
experiencing torsade de pointes or polymorphic ventricular tachycardia (Fig. 3.20).
Diagnosis of LQT often requires administration of the non-specific adrenergic agonist
epinephrine[359, 360].

These correlates suggest similarities between the effects of

ST3Gal4 gene deletion on cardiac electrical signaling in the mouse and many human
arrhythmias and therefore warrant additional studies.

4.4. Could reduced Nav sialylation contribute to the altered excitability and
conduction that present in glycosylation-associated diseases?
Sialic acid affects Nav and Kv function through at least two mechanisms: 1) the
glycosylation signature of each isoform dictates the magnitude of the sialic acid-mediated
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effect[175, 176, 184] and 2) the cell-specific process of glycosylation affects Nav and Kv
activities by changing the number of functional sialic acid residues on a given
isoform[177-179]; for review see[249]. Here, we questioned how a single glycogene
product that is uniformly expressed in the adult heart influences ventricular INa, IK and
electrical signaling. Previous reports demonstrated changes in Nav function and even cell
excitability following desialylation; however, these studies typically removed SAs by
treating the cells with enzymes that would remove all surface SA residues or by
genetically ablating a specialized polysialyltransferase that is only expressed in the
neonatal atria[177-179, 214]. Here we demonstrate that deletion of a glycogene product
responsible for adding a single SA residue during the normal glycosylation process
causes differences in channel function consistent with these previous reports.

The

relatively modest differences appear to significantly affect ventricular excitability that
does not result from a major change in protein trafficking or surface expression. Because
diseases such as CDG often result in reduced sialylation, we also set out to develop a
model that would allow us to question whether such reduced sialylation could be partially
responsible for the altered excitability often observed in these diseases. Specifically, the
mechanisms responsible for the observed symptoms that include hypotonia,
developmental delay, seizures, and dilated or hypertrophic cardiomyopathies with related
arrhythmias, are not yet understood. Consistent with our findings here, nearly all CDG
are associated with hypotonia[215], which may occur as a result of the observed
rightward shift in Nav activation gating. We also observed that a reduction in Nav
sialylation can lead to gains-in-function that may contribute to the other more specific
electrical maladies often observed in these patients including arrhythmias or
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seizures[216, 217], although further experiments are necessary to confirm. The effects of
ST3Gal4 gene deletion on Kv function, which would generally be described as a loss-infunction, are similarly consistent with the observed multi-system symptoms among CDG
patients. ECGs from CDG patients are often described as having elevated ST segments
although, in many cases found in the literature, the ECG patterns are not adequately
quantified and patients are simply described as demonstrating enigmatic arrhythmias[216,
252, 361, 362]. It is likely that the effects of reduced glycosylation, caused by CDG, lead
to overlapping phenotypes through an effect on multiple channel types.

This

combination of effects is likely responsible for the seemingly disparate clinical symptoms
that include hypotonia as well as seizures and arrhythmias.
Chagas disease is caused by the single-celled eukaryotic parasite Trypanasoma
cruzi that infects the heart and affects 16-18 million people in the Americas alone[221].
The organism produces a trans-sialidase that was shown to remove sialic acids from
mammalian cells[218, 253].

Chagas disease is associated with severe pathological

changes in ECGs that include atrial fibrillation, ventricular tachycardia, premature
ventricular contractions as well as various types of conduction block[363, 364] While
many ascribe the effect to the development of fibrosis and/or hypertrophy, conduction
anomalies are more prevalent in those with Chagas disease than in those with other forms
of dilated cardiomyopathy[221]. Additionally, mice infected with two distinct strains of
T.cruzi showed altered ECGs prior to the development of fibrosis or wall thickening
implicating

a

second

mechanism

that

may

involve

the

desialylation

of

glycoproteins[220]. There are other examples of acquired pathologies that may affect
glycosylation indirectly, which then may contribute to the disease symptoms.

The
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muscle LIM protein KO mouse (MLP-/-) is an established and reproducible model for
human heart failure[365-368]. In a 2001 study, Ufret-Vincenty et al. utilized the MLP-/strain to assess how induced heart failure, by MLP gene deletion, affected cardiac
conduction and ventricular APs and Nav function. ECGs of sedated mice indicated a
number of conduction abnormalities in the MLP-/- hearts compared to controls including
an approximate 88% increase in QT interval.

Current-clamp recordings of isolated

ventricular myocytes from MLP-/- mice demonstrated a significant increase in APD90.
Additionally, rapid AP induction caused increased susceptibility to EADs in the MLP-/ventricular myocytes. INa recorded from MLP-/- mice was characterized by a decrease in
maximal current density and shifts in gating consistent with those described here.
Western blot analysis showed a decrease in MLP-/- mouse Nav band intensity as well as a
narrowing of band width and an apparent decrease in molecular weight of the protein
isolated from the MLP-/- strain. Based on these data, the group hypothesized that the Nav
protein from the MLP-/- was aberrantly processed and likely was less glycosylated. To
test this, ventricular myocytes from both groups were treated with neuraminidase.
Compared to untreated control cells, INa from control myocytes treated with
neuraminidase was characterized by similar shifts in gating to those observed in the
untreated and neuraminidase-treated MLP-/- cells and cells from ST3Gal4-/- ventricles.
The study suggested that an acquired change in sialylation, in this case mediated through
a model of heart failure, can impact cardiac excitability. In another study, using an
animal model of ventricular tachycardia that led to heart failure, rapid pacing of canine
hearts caused changes to the glycosylation profile of the Ca2+ handling protein
calsequestrin[224].

These

examples

demonstrate

how

changes

in
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glycosylation/sialylation may contribute to the onset and development of cardiac disease.
The current dogma dictates that, through remodeling, VGICs contribute to
cardiomyopathies and arrhythmias. However, it is apparent based on these examples and
others that glycosylation can be similarly altered through disease or through normal
development and/or vary among different cell/tissue types. Sialic acid affects Nav and Kv
function; therefore it seems reasonable to assume that through changes in the
glycosylation/sialylation of Nav and Kv that it too may contribute to pathological
electrical remodeling. The data presented in this and other studies highlights the potential
contribution of protein glycosylation in cardiomyopathies and introduces it as a novel and
new paradigm that warrants attention when investigating disease that affect cardiac
excitability.
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Chapter 5
Summary

The mouse heart is resistant to arrhythmogenic activity and typically requires
considerable genetic perturbations to manifest significant changes in cardiac conduction
and/or repolarization[47].

Nonetheless, we see here that deletion of a single

sialyltransferase that is uniformly expressed throughout the heart can cause differences in
Nav and Kv function that likely contribute to the differences in cardiac electrical signaling
observed in ST3Gal4-/- mice. Many of these differences mirror those caused by a number
of congenital defects in cardiac Nav and Kv responsible for such human diseases as LQT
and Brugada syndrome[70, 369, 370]. Among the changes in Nav function, we observed
a significant increase in the rate of Nav recovery from fast inactivation that is likely
responsible, at least in part, for the observed decreased cellular and ventricular refractory
periods. Additionally, the rightward shift in Va of Nav from ST3Gal4-/- myocytes would
be expected to contribute to a slowing of cellular conduction as observed by the increase
in time to AP peak, which may be pro-arrhythmogenic. The observed differences in Kv
function likely result in an effective reduction in channel density and repolarization
reserve as evidenced by the increase in APD and ECG recordings following isoproterenol
treatment. Changes in AP waveform, particularly an increase in duration, are a hallmark
of numerous cardiac pathologies that lead to life-threatening arrhythmias. Consistent
with a decreased refractory period and extension of APD is the pro-arrhythmogenic
behavior of the ST3Gal4-/- left ventricular epicardium. Thus, the data presented in this
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study describe a potential novel mechanism by which reduced sialylation may contribute
to the increased susceptibility to arrhythmias observed in individuals with several forms
of CDG and in those afflicted with Chagas disease.

Additionally, the data further

elucidate the role of sialylation in normal cardiac electrical signaling.
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Chapter 6
Future Studies

The ST3Gal4 mouse is likely only a modest representation of glycosylationassociated diseases. In spite of this, the model presents a significant phenotype that
offers insight into the effect of such diseases on cardiac excitability. Future studies will
no doubt attempt to more accurately represent human diseases of glycosylation. For
example, there are a number of mouse models of Chagas disease that may be useful in
similar studies. Additionally, mutated glycogenes that contribute particularly strong
cardiac phenotypes among different CDG can be targeted in other transgenic mouse
studies.

Overall, the biophysical properties of VGICs are often overlooked when

designing strategies to intervene in diseases that relate to electrical excitability. These
studies, while focused on glycosylation, describe how likely alterations in the external
surface potential of a cell may modulate channel activity as well as cell and tissue
excitability.

Changes in VGIC function (gains- or losses-in-function) are pro-

arrhythmogenic and contribute to congenital diseases such as Brugada syndrome and
LQT as well as acquired diseases that include heart failure and hypertrophy[72, 228, 370374]. Specific targeting of ion channels, such as Nav1.5 or Kv11.1, by highly specific
antibodies or attenuated toxins that are derivatized with charged functional groups may
offer a useful means to “tune” electrical excitability. These strategies would offer a
highly specific treatment for many of these diseases, where current techniques often lead
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to unwanted effects on other channel types. Studies investigating the efficacy of such
strategies warrant further investigation.
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